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SUMMARY
vi
1. The aim of this study was to investigate the presynaptic 
interactions that exist between the adrenergic and cholinergic 
nerves in the rat heart.
2. The negative chronotropic response of the heart rate, evoked by
electrical stimulation of the vagus nerve in the pithed rat, was
enhanced when the sympathetic cardio-accelerator nerves were 
stimulated simultaneously.
3. The negative chronotropic response of the heart rate, evoked by
electrical stimulation of the vagus nerve in the anaesthetised
rat, was inhibited by clonidine and potentiated by a combination 
of yohimbine and prazosin.
A. Field stimulation of rat, isolated, spontaneously beating paired 
atria resulted in a complex post-stimulus response. The initial 
negative inotropic component of this response was abolished by 
atropine. The positive inotropic component of this response was 
inhibited by propranolol and guanethidine. Atropine and yohimbine 
both potentiated the positive inotropic component. Clonidine 
inhibited the positive inotropic component only in the presence of 
atropine.
5. Clonidine and acetylcholine inhibited the field stimulation-
3 3evoked overflow of H from atria previously incubated in [ H]-NA.
Yohimbine and atropine potentiated the overflow of H from such
atria.
VI 1
6. Clonidine and acetylcholine inhibited the field stimulation-evoked 
overflow of from atria previously incubated in [^C]-choline.
Atropine and yohimbine potentiated the overflow of from such
atria. The results suggest that field stimulation of atria causes 
the simultaneous release of NA and ACh and that these transmitters 
neuromodulate each others release.
7. Part of the study investigated the role of cyclic nucleotides in 
governing the field stimulation-evoked release of NA and ACh from 
rat atria.
8. Isobutylmethylxanthine potentiated the field stimulation-evoked
O  O
overflow of H from atria previously incubated in [ H]-NA.
9. In the absence and in the presence of atropine, 8-Bromo-cAMP
3
potentiated the field stimulation-evoked overflow of H from atria
O
previously incubated in [ H]-NA.
10. Sodium nitroprusside and 8-Bromo-cGMP both potentiated the field
3
stimulation-evoked overflow of H from atria previously incubated
O
in [ H]-NA. In the presence of atropine, sodium nitroprosside was
3
unable to potentiate H overflow.
11. Sodium nitroprusside inhibited the field stimulation-evoked 
overflow of ^ C  from atria previously incubated in [*■ 1ft-choline 
in the absence and in the presence of prazosin and yohimbine.
The results suggest that sodium nitroprusside indirectly
3
potentiated the overflow of H by removing the cholinergic- 
mediated restraint on NA release.
vi i i
12. In the pithed rat, sodium nitroprusside inhibited the negative 
chronotropic response of the heart rate evoked by electrical 
stimulation of the vagus nerve. In the anaesthetised rat, sodium 
nitroprusside inhibited the same response but this required the 
presence of prazosin and yohimbine.
13. Part of the study investigated the effects of chronically treating 
rats with thyroxine (T^). The level of T^ in the serum was 
increased in rats pretreated with T^, and this was accompanied by 
changes in pre- and post-synaptic receptor sensitivity.
14. Pretreatment with T^ produced a postsynaptic supersensitivity to 
isoprenaline amd a postsynaptic subsensitivity to phenylephrine.
A presynaptic subsensitivity to clonidine, but not to ACh, was 
produced by T^ pretreatment. In these pretreated animals the 
ability of clonidine but not that of ACh to inhibit the field 
stimulation-evoked overflow of H was diminished.
INTRODUCTION
1The modern concept of the autonomic nervous system is based on the 
anatomical and physiological studies of Gaskell and Langley. Gaskell 
demonstrated the functional connection through the white rami 
communicates between the central nervous system and the sympathetic 
chains, and the connections of the grey rami to spinal nerves. Gaskell 
designated the cranial, sacral and thoracolumbar outflows from the 
spinal cord together with the sympathetic trunks and the prevertebral 
and other ganglia as the "involuntary nervous system". Langley first 
proposed the designation " autonomic nervous system", which included 
both the sympathetic and parasympathetic divisions (Dale, 1954). Both 
divisions of the autonomic nervous system are usually tonically 
active. The sympathetic nerves exert an excitatory influence on the 
heart and this is opposed by the inhibitory parasympathetic influence. 
These mutually antagonistic effects are not additive algebraically 
suggesting that complicated interactions occur between the opposing 
nerves (Levy, 1971; 1984).
The classical studies of Otto Loewi (Loewi, 1921; Loewi & Navratil, 
1926 a, b) provided evidence for the release of an active substance 
during stimulation of the vagus nerve of the frog heart. Consequently 
the ground work was laid for the modern concept of neurohormonal 
transmission. In addition, the studies provided an early indication 
of the complex nature of neural control of the heart.
Loewi's observations could not be immediately corroborated because of 
technical difficulties arising from inadvertent stimulation of 
sympathetic fibres in the mixed vagosympathetic trunk. Stimulation of 
the trunk produced cardiac inhibition and, at other times, excitation. 
The intimate anatomical association of sympathetic and parasympathetic
2fibres innervating the heart leads to complex interaction between the 
two divisions of the autonomic nervous system. Such interactions have 
clouded the issue of neural control of the heart with conflicting and 
confusing observations.
There are three possible sites of interactions between the two 
divisions of the autonomic nervous system.
1). In the central nervous system.
2). At the prejunctional level of the terminal nerve fibres.
3). At the postjunctional level of the effector tissue.
Interaction at parasympathetic ganglion cells may arise but this is
less likely in the heart. ____________________________
Much of Chris' study is concerned with the adrenergic-cholinergic
interactions arising at the prejunctional level of the terminal nerve
fibres in the heart of the rat.
NKPROCHEMICAL TRANSMISSION
At the beginning of this century several reports were published which 
postulated the existence of "receptive substances" for adrenaline and 
which demonstrated the similarity between the effects produced by 
adrenaline and sympathetic nerve stimulation on smooth muscle 
(Langley, 1901; 1905; Brodie & Dixon, 1904; Elliot, 1905). It was
suggested that this parallelism occurred because adrenaline stimulated 
sympathetic nerve endings (Brodie & Dixon, 1904). However, from 
studies of denervated tissues it was concluded that adrenaline acted 
directly on smooth muscle (Elliot, 1905). Elliot (1905) suggested 
that the effect of adrenaline was mediated by a "myoneuronal junction" 
whereas Langley referred to this structure as a "receptive-substance" 
(Langley, 1905).
Elliot proposed that nerve stimulation might also involve a 
myoneuronal junction and could therefore be mediated by chemical
transmission. Such a suggestion was proposed by Elliot in 1905 when 
he suggested that sympathetic nerves might release adrenaline.
Unfortunately, the concept was not well received (see Dale, 1953) and, 
consequently, was not pursued for several years. Indeed, experimental 
support was not obtained until it was demonstrated that a chemical 
mediator, "acceleranstoff" was released from sympathetic nerve
terminals innervating the frog heart (Loewi, 1921; Loewi & Navratil, 
1926 a,b). This substance was later found to be adrenaline (von 
Euler, 1946).
Langley (1905) postulated that different receptor subtypes might exist 
when he stated "different receptive substances are formed, the 
responsiveness of which to nervous stimuli varies". The nature of 
these different receptive substances was almost discovered by Henry 
Dale (Dale, 1906; Barger & Dale, 1910). Moreover, the techniques 
initiated by Dale were similar to those adopted by Ahlquist almost 40 
years later, in his successful classification of the adrenergic 
receptor (see below).
Initially, Dale (1906) demonstrated that the motor effects evoked by 
adrenaline or by sympathetic nerve stimulation were reduced or 
transformed into an inhibitory effect ("adrenaline reversal") in the 
presence of ergot preparation. Subsequently, Dale found that the 
relative potencies of and actions produced by a series of amine 
agonists varied in different smooth muscle preparations (Barger & 
Dale, 1910). These results prompted him to suggest that the motor and 
inhibitory effects evoked by adrenaline and nerve stimulation were 
mediated by different receptor types. In this latter report Barger &
Dale did not study the cardiac effect of these amines, an effect which 
had previously been shown to be relatively resistant to ergot (Dale, 
1906). Although Dale's classification for smooth muscle preparations 
was correct, the cardiac effects of sympathomimetic agents are now 
known to be mediated by the normally inhibitory beta-adrenoceptor 
(Ahlquist, 1948).
Following Loewi's demonstration of neurotransmission in the 1920's, 
research into the nature of adrenergic transmission was concentrated 
on determining the identity of this sympathetic mediator. Barger & 
Dale (1910) concluded that noradrenaline (NA) rather than adrenaline 
(Elliot, 1905) was more likely to be the chemical mediator of 
sympathetic nerve transmission. Unhappily, Dale's findings were 
overlooked and the general opinion continued to be that this mediator 
was adrenaline (see von Euler, 1971).
In order to explain the apparent disparity in effects evoked by 
adrenaline and sympathetic nerve stimulation, it was suggested (Cannon 
& Rosenbleuth, 1933) that there were two types of adrenaline 
(Sympathin); Sympathin E and Sympathin I. Cannon & Rosenbleuth 
believed that before Sympathin could activate a muscle cell, it must 
be bound with another substance in the cell and that the evoked 
response should be proportional to the amount of combined substance 
formed. For Sympathin to have such diverse effects then it must be 
bound and/or modified in different ways by different cells; Sympathin 
E being formed in cells which it excites and Sympathin I in cells 
which it inhibits. This sophisticated hypothesis was partially correct 
insofar as it examined post-receptor events and predicted, albeit 
unknowingly, the intracellular production of second messengers. 
Unfortunately, Cannon & Rosenbleuth (1933) proceeded to suggest that
5Sympathin E or I could circulate in the blood stream and activate 
other tissues. Although the Sympathin E and Sympathin I theory 
received support from Stehle & Ellsworth (1937) it was not generally 
accepted (Dale, 1954).
The identity of Sympathin was eventually revealed by von Euler (1946) 
mainly through the multiple biological assay technique pioneered by 
Gaddum & Kwiatowski (1939). Unfortunately, von Euler employed 
Cannon’s terminology and suggested that Sympathin E was noradrenaline 
(NA) and that Sympathin I was adrenaline (1946).
Two years later, Ahlquist classified the adrenergic receptors 
(Ahlquist, 1948). By observing the relative potencies of a series of 
sympathomimetic amines on different test systems Ahlquist postulated 
that there were two receptive substances; the alpha- and beta- 
adrenoceptors. The alpha-adrenoceptor mediated mainly motor effects 
and was activated more easily by NA than by isoprenaline which could 
not be antagonised by ergot. The beta-adrenoceptor mediated mainly 
inhibitory effects (the notable exception being the heart) and was 
stimulated more easily by isoprenaline than by NA.
A parallel similar to that between the effects of adrenaline and 
sympathetic nerve stimulation had been observed for the actions of 
parasympathetic nerve stimulation and the alkaloid muscarine. The 
effects of exogenous muscarine and parasympathetic nerve stimulation 
could be blocked by atropine (Dixon, 1907). The concept of chemical 
transmission was subsequently applied to parasympathetic fibres 
(Dale, 1914; Le Heux, 1919 and 1921; Dale & Dually, 1929; Loewi 1921; 
Loewi & Navratil, 1926 a,b). Proof of the hypothesis was provided by 
the demonstration of the existence of acetylcholine (ACh) in the
perfusion fluid from the mammalian neuromuscular junction following 
stimulation of the motor nerve (Dale e t a l ,  1936). The effect of 
curare-like substances in preventing ACh-induced twitch-like responses 
of skeletal muscle (Brown et al, 1936) lent further support to this 
view as did the ACh intensifying action and the anti-curare effect of 
anti-cholinesterase drugs (Brown, et al, 1936; Eccles, 1937).
MORPHOLOGY
A major problem in investigating neurotransmission and the actions of 
ACh and NA in the heart has been the interactions between the 
sympathetic and parasympathetic nerves (Levy, 1984). Loewi (1921) 
encountered this problem when on stimulating the vagal trunk to the 
heart both acceleration and deceleration of the beating heart was 
noted.
Sympathetic fibres to the heart emerge from the spinal cord with the 
upper five or six thoracic white rami, enter the paravertebral 
sympathetic chains and synapse with the three cervical ganglia and 
with the upper five thoracic ganglia. The heart, therefore, receives 
postganglionic sympathetic fibres from a wide area. The post 
ganglionic sympathetic fibres end around the conducting tissues of the 
heart and also diffusely in the muscle fibres of both atria and 
ventricles. Sympathetic nerve stimulation increases pacemaker 
activity and increases the rate of conduction of impulses through the 
conducting tissue leading to tachycardia. The parasympathetic supply 
to the heart is from the vagus, the preganglionic fibres of which 
synapse with the diffusely arranged ganglion cells situated on the 
atria. Post-ganglionic fibres arising from these ganglion cells
7innervate the conducting tissues of the heart; the sino-atrial node 
and the atrio-ventricular bundle (Bundle of His) (Day, 1979). 
Extensive cholinergic innervation of the atria has been detected 
(Nonindez, 1939) but cholinergic innervation of the ventricles has 
proven more difficult to establish (Higgins et al, 1973). In various 
regions of the cat (Brown, 1976) and rat heart (Stanley et al, 1978) 
the ACh content decreased in the order; right atrium>left atrium>right 
ventricle>left ventricle. Thus, the potential for greatest
interaction between the sympathetic and parasympathetic nerves lies in 
the atria, in particular at the sino-atrial node (Nilsson & Sporrong, 
1970). The terminal cholinergic innervation is composed of long 
chains of varicose fibres similar to the adrenergic innervations. 
Varicosities of both fibres exhibit dense accumulations of vesicles
and are assumed to release the transmitter en passage, that is, in
response to an action potential running from one varicosity to the 
next. The average density of varicosities (adrenergic and
O
cholinergic) in the frog heart is 1.9 varicosities/100 ^m in the
sinus venous. Particularly in the atria there appears to be close 
apposition between adrenergic and cholinergic nerve varicosities and 
the cardiac tissue (Bojsen-Moller & Tranum-Jensen , 1972).
Postganglionic vagal and sympathetic fibres are often in close 
apposition in rat atria and, indeed, they may be surrounded by a 
common Schwann sheath (Ehinger et al, 1970).
Early indications of the presence of cholinergic fibres within 
postganglionic sympathetic nerve trunks came from experiments 
demonstrating that muscarinic blocking agents inhibited and 
anticholinesterases enhanced responses to sympathetic nerve 
stimulation. In several tissues a release of ACh from organs as a
8result of sympathetic stimulation was shown (Campbell, 1970). In 
addition, there is also an apparent simultaneous activation of 
adrenergic and cholinergic nerves in the vagosympathetic trunk. 
Several studies have demonstrated a cardiostimulatory response at the 
cessation of vagal stimulation ( Levy et al 1966; Donald et al, 1967; 
Misu & Kirpekar, 1968).
The ACh likely to influence sympathetic transmission is probably 
contained within discrete cholinergic axons. In most cases they 
represent parasympathetic fibres mixed with the sympathetic nerve 
supply. However, the existence of separate cholinergic-sympathetic 
fibres cannot be excluded (Campbell, 1970). The anatomical evidence 
thus favours an interaction both at a prejunctional and a 
postjunctional level.
In summary, the mammalian heart receives innervation from the 
sympathetic and parasympathetic divisions of the autonomic nervous 
system. These nerves modulate such cardiac activities as sino-atrial 
and atrio-ventricular automaticity, conduction of the cardiac impulses 
and the strength of atrial and ventricular contraction.
NOW-ADRENERGIC, NOH-CHOLIHERGIC TRANSMISSION
In the peripheral autonomic nervous system the presence of non- 
adrenergic, non-cholinergic (NANC) nerves as well as adrenergic and 
cholinergic*^ nerves has been demonstrated both functionally and 
morphologically in isolated preparations of the intestine, (Burnstock, 
1972; Gershon, 1981) urinary bladder (Ambache & Zar, 1970) and blood 
vessels (Lee et al, 1978). Immunohistochemical studies have shown the 
presence of peptide containing nerves, which are distinct from
9adrenergic and cholinergic nerves in the heart (Reinecke et al, 1980; 
Papka et al, 1981; Della et al, 1983). An NANC nerve-mediated
response in the guinea-pig and rat right atria has recently been 
demonstrated (Saito et al, 1986) but has yet to be confirmed. The
NANC nerve-mediated response that followed trans-mural stimulation was 
slow in onset and long lasting and appeared only under certain 
conditions.
In recent years evidence has accumulated which indicates the 
existence of neurones containing more than one neurotransmitter — the 
phenomenon of co-transmission. There are four types of co-transmitter 
neuronesj classification being based on their neurochemical content. 
The locations of such neurones are widespread and include the central 
nervous system, adrenal medulla, preganglionic and postganglionic 
fibres (O’Donohue et al, 1985). Immunohistochemical studies have
demonstrated the existence of neuropeptide Y (NPY) containing nerve 
fibres in atria and to a lesser extent in the ventricles (Allen et al, 
1982). NPY is a 36 amino acid peptide (Tatemoto, 1982) and co-exists 
with NA in many of the sympathetic nerves supplying the cardiovascular 
bed. NPY produces positive inotropic and chronotropic effects on the 
isolated spontaneously-beating guinea-pig atria (Lundberg et al, 
1984). Other studies however, have shown that NPY is without effect 
on Lagendorff preparations and in rat isolated atria (Allen, 1986). 
NPY is reported to be an inhibitor of NA release from adrenergic 
nerves evoked by electrical stimulation in the vas deferens, femoral 
artery and portal vein of the rat (Edvinsson et al, 1987). It seems
unlikely, therefore, that NA and ACh are the sole neurotransmitters in 
the heart. However, the physiological roles of NPY and other putative 
transmitters are still to be elucidated.
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POST-SYNAPTIC RECEPTORS IK THE HEART
Adrenergic receptors are classified into isoreceptors according to the 
relative potencies of various adrenergic agonists and on the 
susceptibility of the receptor to blockade by specific drugs 
(Ahlquist, 1948; Powell & Slater, 1958; Lands, 1967; Furchgott, 
1972). There are alpha and beta adrenergic receptors (adrenoceptors) 
on the myocardium. Receptors for ACh are divided into two classes; 
muscarinic and nicotinic based on their differential sensitivity to 
the alkaloids muscarine and nicotine (Dale, 1914). Several studies 
have been carried out regarding muscarinic isoreceptors. There appears 
to be at least three types of muscarinic receptor classified as M^, 
M^ (Burgen, 1984) and M^ (Michel & Whiting, 1988). This classification 
has developed from observations of the distinct pharmacological and 
biochemical properties of receptors present in various tissues. The 
M 2  receptor subtype is present on the myocardium (Breitweiser & Szabo, 
1985 ).
The consequences of receptor activation by endogenous 
neurotransmitters or by exogenous agonists are complex. The 
parasympathetic neurotransmitter, ACh, regulates atrial rate, nodal 
conduction and atrial and ventricular contractility through activation 
of muscarinic receptors (Higgins et al, 1973). The molecular
mechanisms that mediate these parasympathetic responses have not been 
clearly elucidated. ACh hyperpolarizes atrial cells by increasing 
potassium permeability (Glitsch & Pott, 1978; Fleming et al, 1981) and 
decreases the slow inward current in some preparations (Hutter, 1961; 
Giles & Noble, 1976; Pappano et al, 1982). Biochemical responses also 
accompany cardiac muscarinic receptor activation. These include 
increased cyclic 3 151-guanosine monophosphate (cGMP) production via
11
activation of guanylate cyclase (Mirro et al, 1979; Endoh, 1980 ) and 
stimulation of phosphoitidylinositol metabolism (Brown & Brown, 1983, 
1984). In addit ion, ACh activation of the muscarinic cholinoceptor 
inhibits beta-adrenoceptor-mediated cyclic 3 15'-adenosine
monophosphate (cAMP) production, but has little effect on basal cAMP 
levels (ingebretsen, 1980).
The consequences of adrenergic receptor stimulation are more readily 
understood. It is believed that beta-adrenoceptor activation 
increases the rate and force of contraction of the heart. Both these 
effects are mediated via activation of adenylate cyclase which 
increases cAMP levels which in turn increases the availability of 
intracellular calcium (Loffelholz et al, 1985). The existence of
alpha-adrenoceptors mediating positive inotropic effects in the 
mammalian heart is well established (for review see Scholz et al, 
1986). Recently, it has been suggested that activation of this 
receptor results in the stimulation of phosphoitidylinositol metabolism 
(Schmitz et al, 1987; Scholz et al, 1987).
There is much discussion in the literature as to how postjunctional 
adrenoceptor and cholinoceptor activation interact to control heart 
function (Brown, 1979; Brown & Brown, 1984; Linden et al, 1985).
PRESYNAPTIC RECEPTORS
Noradrenergic nerve endings are concerned with the synthesis, storage, 
release and inactivation of NA. Recent evidence suggests that 
neurotransmitters, hormones and autocoids, such as the prostaglandins, 
can all influence the release of neurotransmitters by acting on 
presynaptic receptors situated on the nerve terminal. This evidence
12
was contrary to the original theory of neurochemical transmission 
which suggested that in the peripheral nervous system the magnitude of 
the tissue response was proportional to the rate of transmitter 
release which was in turn controlled by nerve impulse frequency which 
ultimately was determined centrally (Dale, 1952). This theory was 
challenged intermittently throughout the years but was generally 
accepted. In recent years, however, remarkable changes have occurred 
concerning neurotransmission and it is now generally accepted that 
nerve terminals are invested with a rich variety of receptors that 
regulate transmitter release (Stjarne, 1975; Langer, 1977; Starke, 
1977, 1981).
The effects of agonists and antagonists on the release of transmitter 
in response to nerve stimulation has provided evidence for the theory 
of local regulation. The overflow of the transmitter is that which is 
recovered in the bathing fluid while transmitter release is deemed to 
be the amount actually liberated (Gillespie, 1980).
The first observations regarding the effects of alpha-adrenoceptor 
blockade were derived from experiments in the cat spleen. 
Phenoxybenzamine (PBA), an alpha-adrenoceptor blocking agent, 
increased the stimulation-induced overflow of NA in this preparation 
(Brown & Gillespie, 1957). The increase in transmitter collected in 
the venous effluent was attributed to a blockade of the post-synaptic 
alpha-adrenoceptors by PBA, preventing the released NA from combining 
with the receptors. Overflow of transmitter also increased in relation 
to the frequency of stimulation; an effect attributed to flooding the 
receptors with transmitter.
This suggestion was challenged by Paton (1960), who performed similar 
experiments on the adrenal gland, a tissue devoid of post-synaptic 
alpha-adrenoceptors. Similar increases in transmitter overflow were 
observed in response to increasing the frequency of stimulation. Paton 
suggested that the released amines from both the adrenals and the 
sympathetic nerves were taken back into the cell from which they were 
released. Thus, the increase in transmitter overflow at higher 
frequencies of stimulation was caused by the reduction in time 
available for uptake of the amine. The existence of a neuronal uptake 
mechanism (Uptake 1) was soon established (Hertting et al, 1961, a). 
Uptake 1 was found to be blocked by cocaine (Whitby et al, 1960) and 
PBA (Hertting et al, 1961, b). Later, a second extraneuronal uptake 
mechanism (Uptake 2) that could be blocked by PBA but not by cocaine 
was characterised (Iversen, 1965; Avakian & Gillespie, 1968). Since 
■ low concentrations of PBA could inhibit neuronal uptake of NA 
(Iversen, 1965; Eisenfield et al, 1967), it was suggested that the
increase in NA overflow could be related to the blockade of either or 
both of these sites of loss for the released transmitter.
The suggestion was however unfounded, since complete inhibition of 
neuronal uptake of NA can be achieved with agents which do not block 
the alpha-adrenoceptors such as cocaine or desipramine without 
producing a concomitant increase in transmitter overflow (Blakely jit_ 
al, 1963; Geffen, 1965). In addition there is evidence that alpha- 
adrenoceptor antagonists increase transmitter overflow either at 
concentrations that failed to inhibit neuronal uptake (Starke, 1971; 
Enero et al, 1972) or even in the presence of potent inhibitors of the 
neuronal amine pump (Starke, 1977). These observations prompted 
several independent laboratories to suggest that an increase in the 
amount of NA released by nerve impulse could occur in the presence of
14
alpha-adrenoceptor antagonists (Haggendal, 1970; Langer 1970; 
McCulloch et al, 1972).
Dopamine beta hydroxylase is an enzyme present in adrenergic storage 
vesicles. It is released with NA by exocytosis during nerve 
stimulation and is not affected by uptake or degradative enzymes. An 
increase in overflow of this enzyme reflects an increase in 
transmitter release. In support of the view that alpha-adrenoceptor 
antagonists could increase the amount of NA released by nerve impulse 
it was reported that the release of the enzyme dopamine beta 
hydroxylase was increased when neurotransmission in the cat perfused 
spleen was studied in the presence of PBA or phentolamine (De Potter 
et al, 1971). On the basis of the enhanced exocytotic release of NA 
observed with alpha-adrenoceptor blocking agents the presence of 
presynaptic alpha-adrenoceptors involved in the regulation of NA 
release was postulated (Farnebo & Hamberger, 1971; Kirpekar & Puig, 
1971; Langer et al, 1971; Starke, 1971). Activation of these alpha- 
adrenoceptors is believed to inhibit NA release and it has been 
suggested that they form part of a negative feedback control mechanism 
by which the transmitter may regulate its own release (Langer, 1980; 
Starke, 1977). Several pieces of evidence support this hypothesis.
Alpha-adrenoceptor antagonists enhance the stimulation-evoked release 
of NA in almost all adrenergically-innervated tissues examined, 
irrespective of the nature of the postsynaptic receptors on the 
effector. Enhancement of the evoked-release of NA occurs in the 
presence of uptake blockers. Antagonists of alpha-adrenoceptors 
enhance the stimulation-evoked release of the enzyme dopamine beta 
hydroxylase, an effect which is not seen with amine uptake blockers. A 
wide range of alpha-adrenoceptor agonists decrease the evoked release
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of NA in almost all noradrenergically-innervated tissues examined. In 
addition, alpha-adrenoceptor agonists abolish the ability of alpha- 
adrenoceptor antagonists to facilitate the stimulation-evoked release 
of NA. Antagonists of alpha-adrenoceptors block or reduce the 
inhibitory effects on neurotransmitter release produced by alpha- 
adrenoceptor agonists. Finally, inactive enantiomers such as (+)-NA 
fail to depress the evoked release of NA (Westfall, 1984).
The theory of presynaptic receptors regulating transmitter release is 
not readily accepted by all workers. Perhaps one observation in 
particular has caused the voice of dissent to be raised. At high 
frequencies of stimulation alpha-adrenoceptor antagonists have little 
effect on transmitter release (Brown & Gillespie, 1957). In much the 
same way alpha-adrenoceptor agonists also have little effect on 
transmitter release at high frequencies of stimulation. The latter 
observation is more readily explained. It is possible that at high 
frequencies of stimulation the concentration of neurally-released NA 
is such that the presynaptic alpha-adrenoceptors are fully activated, 
thus a maximum inhibition is being exerted and additional exogenous 
agonist is ineffective (Langer, 1977; Starke, 1977). The observation 
that antagonists have little effect at high frequencies of stimulation 
cannot be explained in the same way. If at high frequencies of 
stimulation NA is exerting a maximum inhibition by activating 
presynaptic alpha-adrenoceptors then alpha-antagonists should be able 
to further enhance the release of transmitter. In an attempt to 
explain this anomaly an alternative hypothesis has been postulated 
(Kalsner, 1984; Kalsner & Quillan, 1984; Kalsner, 1985). The alpha- 
antagonist-induced increases in overflow should be proportional to the 
level of ongoing feedback in the absence of antagonists and explicable 
in terms of the amount of NA in the synapse to activate presynaptic
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receptors during stimulation (Forsyth, 1987). However in a variety of 
tissues from several species this was not found (Kalsner & Quillan, 
1984). The alpha-adrenoceptor antagonists proved to be most effective 
at low frequencies of stimulation when the concentration of 
transmitter in the synapse was low. The release of transmitter from 
sympathetic nerves is directly related to the duration of the action 
potential. If the duration of the action potential is prolonged, the 
calcium channels stay open longer leading to greater entry of calcium 
and to an increased release of transmitter (Baker, 1971). Yohimbine 
and PBA may prolong the duration of depolarisation by indirect 
modification of the calcium gating mechanism (Kalsner, 1985). This 
hypothesis is substantiated by the potentiating action of 
tetraethylammonium (TEA) on transmitter overflow. TEA selectively 
blocks outward potassium permeability directly, causing prolongation 
of the action potential and consequently neurosecretion (Kalsner & 
Quillan, 1984).
Although both the pre- and the post-synaptic alpha-adrenoceptors are 
stimulated by alpha-adrenoceptor agonists and blocked by alpha- 
adrenoceptor antagonists, it appears that the post-synaptic alpha- 
adrenoceptors mediating the responses of the effector organ are not 
identical with the presynaptic alpha-adrenoceptors that regulate the 
release of NA during nerve stimulation. Originally, alpha- 
adrenoceptors were subclassified on the basis of differing anatomical 
location before complete analysis of their sensitivity to agonists or 
antagonists could be assessed; alpha^ was the post-junctional receptor 
whereas alpha2 was the prejunctional receptor (Langer, 1974). The 
prejunctional or alpha2 receptors were presumed to be located on or 
near the terminal regions of sympathetic nerves. In accordance with 
receptor theory, it has been demonstrated that the relative potency of
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a series of agonists differed markedly at the pre- and post-junctional 
site in the rabbit pulmonary artery (Starke et al, 1975). Generally, 
agonists such as clonidine, alpha-methyl NA and tramazoline were more 
potent at the prejunctional site whereas phenylephrine and methoxamine 
were more potent postjunctionally.
The demonstration that alph^ adrenoceptors were also located in non­
neuronal tissues eg platelets, invalidated Langer's (1974) original 
anatomical classification and receptors are now designated purely on 
the basis of drug selectivity (Starke & Langer, 1979). Recent 
studies, based on drug selectivity, have demonstrated the presence of 
presynaptic alpha^-adrenoceptors in the pithed rat heart and vas 
deferens (Docherty, 1984). Activation of these receptors inhibits NA 
release as reflected by a decreased postjunctional response to nerve 
stimulation.
In addition to the presynaptic alpha-adrenoceptors regulating NA 
release it appears that the adrenergic nerve ending is endowed with a 
variety of receptors that serve the same purpose. For example, 
facilitation of the stimulation-evoked release of NA through 
presynaptic beta-adrenoceptors has been proposed (Langer et al,
1974). Further support for the presence and role of presynaptic beta- 
adrenoceptors was obtained in experiments in which exposure to low 
concentrations of isoprenaline facilitated release of NA during low 
frequency nerve stimulation (Adler-Graschinsky & Langer, 1975; Pelayo 
et al, 1978).
Experimental evidence obtained with specific agonists suggest that the 
presynaptic facilitatory beta-adrenoceptors might be of the beta2 
subtype (Gillespie,1980). However in skeletal muscle of the cat the
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presynaptic beta-adrenoceptors are blocked by metoprolol a beta^- 
adrenoceptor antagonist suggesting that in this case they are of the 
beta^ subtype. This suggests that the nature of the presynaptic beta- 
adrenoceptor may differ between the somatic and the autonomic nerves.
It is possible that presynaptic facilitatory beta-adrenoceptors are 
mainly activated by circulating adrenaline to enhance noradrenergic 
neurotransmission. This view is supported by the observation that 
when adrenergic nerves are labelled with adrenaline (instead of NA) 
propranolol, the beta-adrenoceptor antagonist, becomes more effective 
in reducing transmitter release elicited by sympathetic nerve 
stimulation (Rand et al, 1979).
In addition, there is evidence for the existence of inhibitory 
dopamine receptors situated on peripheral noradrenergic nerve endings. 
These presynaptic dopamine receptors designated to be of the DA2  
subtype appear to be responsible for the hypotension and bradycardia 
produced by certain dopamine agonists (Lokhandwala & Jandyala, 1979).
Electrically-stimulated release of NA can be regulated by morphine 
acting via presynaptic opiate receptors (Dubocovich & Langer, 1980; 
Forsyth, 1987 ) and inhibited by prostaglandins of the E series
(Hedqvist, 1970), by adenosine and adenine nucleotides (Hedqvist & 
Fredholm, 1976) and by serotonin acting on presynaptic serotonin 
receptors on the noradrenergic nerve terminals of vascular tissues 
(McGrath, 1977).
In addition to the presynaptic receptors mentioned above there exists 
an inhibitory presynaptic, muscarinic receptor. Activation of 
muscarinic receptors on adrenergic nerve endings results in inhibition
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of NA release. These receptors are not only activated by drugs but 
also by the endogenous transmitter released from cholinergic nerves. 
The studies that ultimately led to the concept of muscarinic 
inhibition of NA release were initially designed to investigate the 
effects of nicotinic drugs on the peripheral post-ganglionic 
adrenergic nerve fibre. The rabbit perfused heart preparation was 
used for this work as it permitted pre-ganglionic stimulation of the 
vagus nerve. In these experiments the nicotinic actions of ACh were 
compared with those of dimethylpiperazinium (DMPP). Whereas ACh has 
both muscarinic and nicotinic effects, DMPP is a purely nicotinic 
agonist. As often occurs, discoveries such as these depend on 
serendipity and indeed, it was noted that after accidental omission of 
atropine (normally present in the perfusion fluid) that the 
transmitter output into the perfusion fluid was greatly inhibited by 
ACh but not by DMPP. It was soon established that muscarinic receptor 
activation or inhibition did not interfere with the neuronal uptake or
output of NA from the heart. Atropine did not enhance the amine
liberating effect of ACh (via nicotinic receptors) by delaying its
metabolism. The post synaptic effects of cholinomimetic drugs on 
heart rate, myocardial tension development and coronary flow could not 
explain the facilitatory action of atropine on NA overflow evoked by 
ACh (Lindmar et al, 1968).
These findings led to the suggestion that the peripheral adrenergic 
nerve fibre contains inhibitory muscarinic receptors in addition to 
the excitatory nicotinic receptors mediating NA release (Lindmar _et_ 
al, 1968). It was subsequently shown that exogenous application of 
ACh could also inhibit electrically-evoked NA output in the rabbit 
perfused heart (Loffelholz & Muscholl, 1969). This effect was
blocked by atropine but not by hexamethonium or DMPP (Loffelholz and
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Muscholl, 1969), thus confirming the clear distinction between the 
excitatory nicotinic effect and inhibitory muscarinic effect on 
transmitter release (Muscholl, 1980).
PRESYNAPTIC ADRENERGIC-CHOLINERGIC INTER ACTIONS IN THE HEART
The possibility of cholinergic-adrenergic interactions has been the 
subject of much experimentation and several review articles (Burn & 
Rand, 1962; Campbell, 1970; Kosterlitz & Lees, 1972; Fozard, 1979; 
Levy, 1971 and 1984). Since the discovery of the autonomic grand 
plexus in which terminal cholinergic and adrenergic axons run side by 
side without intervention of insulating Schwann cell processes 
(Hillarp, 1959), many such fibres have been found in a variety of 
systems. These include the iris (Ehinger et al, 1970), vas deferens 
(Thoenen & Tranzer, 1968), myenteric plexus of the gut (Manber & 
Gershon, 1979) and atria ( Thoenen & Tranzer, 1968; Ehinger et al, 
1970).
There is now a large body of evidence which suggests that simultaneous 
stimulation of adrenergic and cholinergic nerves results in endogenous 
ACh-mediated inhibition of release of NA by activation of presynaptic 
muscarinic receptors situated on adrenergic nerve terminals. 
Transmitter release studies have revealed such a mechanism in hearts 
from cat (Haeusler et al, 1968), dog (Levy & Blattberg, 1976), and rat 
(Fuder et al, 1982;) but not in the guinea-pig (Story et al, 1975) or 
chicken (Engel & Loffelholz, 1976). The case for endogenous 
cholinergic regulation of NA release is therefore well documented.
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Recent evidence suggests that endogenous ACh and NA regulate ACh 
release from cholinergic nerves, particularly in the gut. For example, 
exogenous ACh inhibits the field-stimulated induced release of [^H] 
from guinea-pig ileum previously incubated in [^H]-choline. This 
inhibition could be blocked by atropine (Fosbraey & Johnson, 1980). 
A reciprocal adrenergic-cholinergic inhibitory interaction has been 
proposed following experiments carried out on the rabbit jejunum. 
This study involved simultaneous stimulation of the perivascular and 
cholinergic nerves. Under such circumstances the release of [^H] was 
inhibited. Sympathetic denervation by 6-hydroxydopamine (6-OHDA) pre­
treatment prevented this inhibition, suggesting an adrenergic 
involvement in the inhibition of ACh release. Since atropine enhanced 
the release of [ H]-NA during simultaneous nerve stimulation it 
appears that ACh inhibits the release of NA in the rabbit jejunum 
(Manber & Gershon, 1979). Morphological evidence also supports the 
view that adrenergic nerves synapse with cholinergic nerves in the 
myenteric plexus suggesting that a reciprocal adrenergic-cholinergic 
inhibitory interaction is not unreasonable. There is considerable 
pharmacological evidence for the existence of presynaptic alpha- 
adrenoceptors on the parasympathetic nerves in the gut (Knoll & Vizi, 
1970; Wickberg, 1978; Davey, 1980) in addition to the presynaptic 
muscarinic receptors proposed by Fosbraey & Johnson (1980).
There exists, therefore, a substantial body of evidence for a 
reciprocal adrenergic-cholinergic inhibition in the gut. Such a 
mechanism would require the release of NA from sympathetic nerves to 
be inhibited by the activation of prejunctional muscarinic receptors 
by ACh, released from the adjacent parasympathetic nerves and 
similarly, the release of ACh to be inhibited by activation of
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prejunctional alpha-adrenoceptors by endogenous NA. The evidence is 
much less substantial for such a system occurring in cardiac tissue.
However,such an inhibitory cholinergic-adrenergic interaction has been 
proposed for the heart (Rand et al, 1975 and 1980), although little 
evidence has emerged to verify its existence. Differing experimental 
techniques and species differences have prevented verification of such 
an interaction. Thus, the guinea-pig atria has produced conflicting 
and confusing results over the last few years. For example, no 
evidence was found for inhibitory presynaptic receptors on the 
cholinergic nerve terminal in this preparation (Lew & Angus, 1983). 
Furthermore, no evidence was found for the inhibition of cholinergic 
transmission by NA released from sympathetic nerves. In contrast to 
this, by examining the field-stimulated induced release of [%]-ACh
O
from atria previously incubated in [ H]-choline it can be shown that 
exogenous NA inhibits the release of ACh from the guinea-pig atria 
(Loiacono & Story, 1986). The inhibitory effect of exogenous NA was 
abolished by idazoxau and phentolamine but not by prazosin suggesting 
the inhibition was mediated by activation of presynaptic alpha2 ~
O
adrenoceptors. However, since clonidine could not inhibit [ H]-ACh 
release, there remains some doubt as to the nature of the receptor. 
In addition to this anomaly, NA was ineffective in blocking the 
negative chronotropic responses to extrinsic nerve stimulation in 
atrial preparations with a branch of the vagus intact. Since neither 
phentolamine, idazoxan nor prazosin had any effect on the stimulation 
induced release of [ H]-ACh, no evidence for an endogenous NA-mediated 
attenuation of ACh release has been found in the guinea-pig atria. 
Similarly, in the chick heart no evidence was found for presynaptic 
alpha-adrenoceptors on cholinergic nerve terminals or for an
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inhibitory action of endogenous NA o n  ACh release (Loffelholz et al,
1984).
Studies on the rat atria have, however, proved fruitful. Potassium-
3 ^induced [ H]-overflow from rat atria previously incubated in [ H]-
choline can be inhibited by ACh and potentiated by atropine (Wetzel et
al, 1985). This suggests that a mechanism for muscarinic feedback
inhibition exists that is analogous to the autoregulation of NA
release by alpha-adrenoceptors on adrenergic nerve endings (Wetzel &
Brown, 1985). In addition alpha-adrenoceptor agonists inhibit the
O
potassium-evoked release of [JH]-ACh via a presynaptic alpha^- 
adrenoceptor situated on the cholinergic nerve terminal (Wetzel et al,
1985).
The rat atria provides a good opportunity to examine possible 
cholinergic-adrenergic presynaptic interactions. This thesis will seek 
to investigate this possibility and to examine the effects of such an 
interaction on the field-stimulated release of NA and ACh.
UNDERLYING MECHANISMS OF TRANSMITTER RELEASE
The mechanisms by which activation of presynaptic beta-adrenoceptors 
facilitate release of transmitter and by which activation of 
presynaptic muscarinic cholinoceptors and alpha-adrenoceptors inhibit 
the release of NA has not yet been elucidated. With more recent 
evidence suggesting the presence of presynaptic inhibitory muscarinic 
cholinoceptors and alpha-adrenoceptors on the cholinergic nerve 
terminals (see above), there exists perhaps a new opportunity to 
examine events which regulate transmitter release. Transmitter 
release appears to be promoted by increasing cytosolic free calcium
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concentration ( Blaustein, 1979). A nerve action potential opens 
calcium voltage-operated channels in the varicosities thus increasing 
the cytosolic free calcium concentration. This increases calcium 
binding to the protein calmodulin. The calcium-calmodulin complex 
activates kinases which trigger the release of transmitter (Illes,
1986). The mechanism by which presynaptic receptor activation 
perturbs this system is unknown. One possible hypothesis is that the 
adrenoceptor and cholinoceptor effects are due to alterations in 
adenylate cyclase activity and consequently cyclic AMP formation 
(Jakobs, 1985; Illes, 1986). It is suggested that the alpha2 _ 
adrenoceptor and possibly the muscarinic cholinoceptor are coupled to 
adenylate cyclase via the inhibitory G protein G^. When activated by 
their respective agonists the receptors reduce cAMP production and 
consequently protein kinase A (PKA) dependent phosphorylation. It is 
thought that PKA and the calcium-calmodulin complex feed into the same 
phosphorylation pathway. PKA increases the calcium sensitivity of the 
release process. Therefore, agents that reduce cAMP production reduce 
calcium sensitivity and transmitter release. Conversely, facilitatory 
presynaptic beta-adrenoceptors are thought to be coupled to adenylate 
cyclase via the stimulatory G protein Gg. Activation of beta- 
adrenoceptors enhances adenylate cyclase activity, increases cAMP 
production and promotes transmitter release. Additionally, PKA causes 
phosphorylation of voltage-operated calcium channels causing an 
increase in intracellular calcium (Rosenthal & Schulz, 1987). 
Therefore, presynaptic receptor activation can affect transmitter 
release in two ways, first by affecting the calcium sensitivity of the 
release process via PKA and secondly, by affecting calcium influx also 
via PKA.
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It has been suggested that the presynaptic muscarinic cholinoceptor 
and the presynaptic alpha2 ~adrenoceptor on the adrenergic nerve 
terminal in the rat atria are linked to a common pathway, since the 
effect of ACh on transmitter release was enhanced in the presence of 
the alpha2 ~adrenoceptor blocking agent phentolamine (Loiacono et al, 
1985). A possible candidate for such a pathway is the phosphorylation 
pathway described above.
Further support for the involvement of cyclic nucleotides in 
transmitter release is provided by the observation that stimulation- 
induced release of NA is enhanced by cell permeable analogues of cAMP 
(dibutyry1-cAMP, 8-bromo cAMP) as well as phosphodiesterase inhibitors 
that inhibit the breakdown of cAMP (Wooten et al, 1973; Stjarne et al, 
1979; Hentrich et al, 1985) and the adenylate cyclase activator
forskolin (Hovevei-Sion et al, 1983; Alberts et al, 1985).
Recent studies in mouse atria (Johnston et al, 1987) have shown that 
prejunctional beta-adrenoceptor effects were mediated through 
adenylate cyclase while the inhibitory alpha-adrenoceptor effects were 
not. In addition, it was found that the cGMP analogue, 8-bromo cGMP 
facilitated the stimulated-induced release of NA. This effect, also 
reported by Cubeddu (Cubeddu et al, 1975), was assigned to inhibition 
of cAMP phosphodiesterase activity. The selective cGMP
phosphodiesterase inhibitor M & B 22948 (9yM) failed to enhance the 
stimulation-induced overflow of NA. However at (90y/M) an enhancement 
was observed.
The enhancement of NA release by permeant cGMP analogues is not a 
common observation, indeed increases in neuronal cGMP levels are 
usually associated with inhibition of NA release (Pelayo et al, 1978).
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The presence of a calcium-dependent presynaptic mechanism for the 
generation of cGMP has been described (O’Dea & Zatz, 1976). This 
cGMP generating system appeared to be linked to an alpha-adrenoceptor 
because the increased cGMP levels obtained by either NA or potassium 
were blocked by alpha-adrenoceptor blocking agents. Exposure to 
dibutyryl cGMP reduced the potassium-evoked release of [^H]-NA from 
the rat pineal. In addition, a decrease in the stimulation-evoked 
release of [ H]-NA was observed during exposure to an inhibitor of a 
cGMP phosphodiesterase (Pelayo et al, 1978). These results suggest 
that, in the rat pineal gland, cGMP may be a link in the chain of 
events following activation of presynaptic alpha-adrenoceptors and may 
lead to a decrease in the release of NA. In contrast, in the cat 
perfused spleen and in the rat vas deferens analogues of cGMP did 
not affect the release of NA during nerve stimulation (Langer, 1980). 
However, an important effect of cGMP was observed in cortical slices 
of rat brain. In this preparation cGMP derivatives reduced the 
stimulation evoked release of ACh through a presynaptic muscarinic 
receptor (Yonehara et al, 1980). This observation has serious 
implications when examining the role of cyclic nucleotides in the 
atria, due to the possible influence that the adrenergic and 
cholinergic systems may exert over one another.
Therefore, in view of the close apposition of adrenergic and 
cholinergic nerves in preparations such as the atria (Ehinger et al, 
1970) and the possible interactions between the two divisions of the 
autonomic nervous system (Rand et al, 1975 ; 1980) it is perhaps
imprudent to assign drug induced effects to one aspect of the system 
without considering that the drugs may also be affecting the other 
aspect. Consequently, the apparent direct effects of drugs on the 
sympathetic division of the autonomic nervous system may be
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indirectly due to an action on cholinergic nerves or to a 
combination of both effects. Due to interaction between the two sets 
of nerves a misinterpretation of results may occur. This thesis will 
examine the role of cyclic nucleotides in transmitter release in the 
rat atria and will attempt to interpret the results achieved against a 
background of possible adrenergic cholinergic interaction.
SENSITIVITY CHANGES IH AUTONOMIC EFFECTORS
The survival of the organism is often governed by its ability to adapt 
to its own environment. Such adaptations, as prompted by the 
environment, range from evolutionary changes taking many years to 
develop, to the rapid adaptions required to protect the animal from 
hostility (Gibson, 1981). Rapid responses often depend on the release 
of chemical mediators which provide a physiological means of adapting 
tissue sensitivity to meet the demands of the animal (Guyton, 1971). 
The continued existence of an organism is maintained by two systems of 
prime importance; the autonomic nervous system and the endocrine 
glands (Bernard, 1878). Both of these systems are involved in
influencing the sensitivity of cardiac muscle. Under certain
conditions skeletal, cardiac or smooth muscle can be rendered either 
supersensitive or subsensitive to various stimuli. Supersensitivity is
believed to have occurred when the amount of stimulant required to
produce a given response is less than normal. The converse is true 
when subsensitivity has occurred; that is a certain amount of agonist 
produces a smaller response.
Supersensitivity
Supersensitivity (Cannon & Rosenbleuth, 1949; Trendelenburg, 1972; 
Trendelenburg and Graefe, 1975; Fleming et al, 1973; Thesleff, 1974; 
Westfall, 1981) generally occurs as a result of the removal of a tonic 
stimulus. Surgical denervation provided an early opportunity to 
examine the phenomenon of supersensitivity (Budge, 1855). Denervation 
of the cat nictitating membrane results in two types of 
supersensitivity (Langer & Trendelenburg, 1966; Trendelenburg, 1966), 
one of which was specific for NA, the other being non-specific. The 
specific supersensitivity produced to NA was due to the destruction of 
a major site of loss for exogenously administered NA, that is, the 
adrenergic neurone. As a consequence of the removal of the site of 
loss, the concentration of agonist that reaches the receptors of the 
effector organ increases, resulting in an enhanced response.
Non-specific supersensitivity has been attributed to an increase in 
receptor number (Langer & Trendelenburg, 1968; Bito & Danson, 1970). 
Surgical denervation does not produce an immediate change in 
sensitivity. The phenomenon is slow in onset occurring several days 
after surgery and the sensitivity changes occur at several receptors. 
It is unlikely that the supersensitivity arises solely at the site of 
agonist receptor interaction. It is possible that the system is 
affected beyond the plasma membrane for example, at sites where the 
excitation of several receptors converge on a common biochemical 
pathway (Hudgins & Fleming, 1968; Fleming, 1968).
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A leftward displacement of the dose response for one or more agonists 
reflects supersensitivity of a tissue to a receptor ligand (Cannon & 
Rosenbleuth, 1949). In such circumstances the maximum response of the 
tissue remains unchanged while responses to submaximal doses of the 
agonist are increased. However in some situations the maximum
response of the tissue is increased and this can also be interpreted 
as a type of supersensitivity (Pollock et al, 1972; Gibson & Pollock,
1975).
Desensitisation of a tissue to a receptor ligand, or subsensitivity, 
is reflected in a rightward displacement of the dose response curve 
(Rang & Ritter, 1969). As with supersensitivity, a decrease in the 
maximum response o£ the tissue, coupled with, or in the absence of , a 
rightward displacement of the dose response curve can be interpreted 
as subsensitivity (Waud, 1975). Two types of desensitisation are 
recognised, namely homologous and heterologous.
The term heterologous desensitisation describes the non-specific 
reduction in sensitivity that occurs when cells are incubated with one 
agonist and subsequently found to be subsensitive not only to that 
agonist, but to several others (Su et al, 1970). Heterologous
desensitisation involves functional uncoupling of receptors in the 
absence of sequestration or down-regulation (Harden, 1983).
Homologous desensitisation is the term used to described the specific 
desensitisation that occurs when cells are re-challenged with the same 
agonist used in the initial exposure. In this situation agonists 
other than that used in the initial exposure produce a normal response
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of the tissue (Su et al, 1976). In the case of beta-adrenoceptors, 
this type of desensitisation is thought to involve the sequestration 
of the receptors away from the plasma membrane. The sequestered 
receptors may then undergo degradation (Harden, 1983; Perkins & 
Hertel, 1987).
Changes in the sensitivity of a tissue to a specific receptor ligand 
are usually examined by one of two techniques. First, by using direct 
receptor labelling techniques, radio-ligand binding, and secondly by 
more traditional pharmacological methods using isolated tissues or in 
situ experiments. Each technique has both advantages and
disadvantages. Radio-ligand binding minimises the problem of drug- 
receptor equilibirum and eliminates the effects of drugs distal to the 
receptor (Minneman & Molinoff, 1980 ; Nahorski, 1981). This
technique, which examines the specific binding of radiolabelled high 
affinity agonists or antagonists, has been successful in demonstrating 
that alterations in receptor number may contribute to at least some 
forms of drug induced desensitisation (Creese & Sibley, 1981; Harden, 
1983). In these experiments the lack of a biological response, often 
due to the fact that highly specific antagonists with little intrinsic 
activity are employed, is a disadvantage. This can be overcome by 
employing traditional pharmacological techniques that allow the 
biological response to be measured. There is perhaps an advantage in 
being able to detect alterations in the mechanisms linking receptor 
activation to a change in cellular response.
Circulating hormones released from the endocrine glands are known to 
exert a regulatory influence on distant tissues. For example, 
corticosteroids enhance the response of smooth muscle to 
catecholamines (Gibson & Pollock, 1975). The thyroid hormones,
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triiodothyronine (Tg) and thyroxine (T^) are released from the thyroid 
gland which is under the control of a pituitary hormone, thyrotrophin. 
The thyroid hormones have wide ranging effects throughout the body on 
growth and metabolism. They also exert a strong influence on the 
sensitivity of sympathetically-innervated tissues to agonists (Gibson, 
1981).
The similarity between the symptoms of hyperthyroidism and increased 
activity of the sympathetic nervous system is long established (Reith, 
1865). It appears that neuro-effector response to catecholamines are 
enhanced in hyperthyroidism and diminished in hypothyroidism 
(Waldstein, 1966). In some circumstances, however, increased 
sympathetic activity is not observed in conditions of hyperthyroidism 
(MacMillan & Rand, 1962) and therefore the role of thyroidal influence 
governing the sympathetic nervous system is far from being elucidated.
Most studies on the effects of thyroid hormones on autonomic effector 
sensitivity have involved the use of cardiac tissue. Hyperthyroidism 
increases the sensitivity of the heart to beta-adrenoceptor agonists, 
and decreases the sensitivity of the heart to alpha-adrenoceptor 
agonists. Conversely, hypothyroidism enhances the response to alpha- 
adrenoceptor agonists and diminishes that of beta-adrenoceptor 
agonists (McNeill, 1987; Kunos, 1977). These changes in cardiac 
sensitivity are supported by ligand binding studies, which indicate 
that hyperthyroidism increases the number of beta-adrenoceptors and 
decreases the number of alpha-adrenoceptors, whilst hypothyroidism 
exerts the opposite effect (Kunos, 1977). In addition, thyroid 
hormones can apparently regulate the number of muscarinic receptors in 
the heart; hyperthyroidism decreases and hypothyroidism increases the 
number of muscarinic receptors (Sharma & Banerjee, 1977). Indeed, the
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actions of the thyroid hormones are complex and may exert 
intracellular effects in addition to those at the level of the
receptor ( Tse et al, 1980; McNeill, 1987).
The apparent parallel changes in adrenergic receptor sensitivity and 
number led to the suggestion that there might be a single adrenoceptor 
that can exist as either the alpha- or the beta-adrenoceptor and which 
can interconvert to one or other according to the circulatory levels
of (Kunos, 1977). This theory, unfortunately, fails to take into
account the existence of prejunctional alpha- and beta-adrenoceptors 
known to exist in the heart and the effect that thyroid hormones may 
exert on the sensitivity and number of these receptors. Generally, 
ligand binding studies fail to take into account the anatomical site 
of non-neuronal and neuronal receptors. However, one study attempted 
to calculate the number of presynaptic alpha-adrenoceptors by 
comparing receptor binding in control and chemically sympatheetomised 
atria. It was found that 33% of alpha-adrenoceptors appeared to be 
localised on the prejunctional sites (Sharma & Banerjee, 1978). Some 
doubt must be cast on this study however as the chemical sympathectomy 
will also affect the number and sensitivity of postjunctional 
receptors (Chiu, 1978; Hawthorn & Broadley, 1984).
It is difficult to accept a theory that proposes an allosteric change 
in a single receptor when the hypothesis fails to take into account 
that the proposed changes in receptor number and sensitivity occur at 
different anatomical sites.
Surprisingly little attention has been focussed on the effects of 
thyroid hormones on presynaptic receptors. This is despite the 
important role of these receptors in regulating transmitter release
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at the neuroeffector junction (Gillespie, 1980). Part of this study, 
therefore, investigated the effects of excess levels on the
sensitivity of both pre- and post-synaptic receptors in the rat atria.
The heart possesses a dense adrenergic and cholinergic innervation. 
Since the earliest studies this has proved to be both advantageous and 
disadvantageous to pharmacological examination. With this in mind the 
study set out to determine:
(1) The extent of presynaptic adrenergic-cholinergic interaction in 
the rat heart
(2) To what extent does such an interaction influence the effect of 
drugs on the release of transmitter in the heart.
(3) Are cyclic nucleotides involved in the release of 
neurotransmitters in the heart.
(A) What effect does altering the levels of circulating T^ have on 
the sensitivity of pre- and post-synaptic receptors.
MATERIALS AND METHODS
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MECHANICAL RESPONSES OF THE RAT ATRIA
i) Preparation of Tissues
Adult, male, Wistar rats (250-320g) were killed by stunning and
exsanguination. The thorax was opened and the heart was rapidly 
removed. The left and right atria were separated from the ventricles 
and placed in a beaker containing Krebs bicarbonate solution of the 
following composition (mM): NaCl (118.1), KC1 (4.7), MgSO^ (1.0),
KH2POa (1.2), CaCl2 (2.5), NaHC03 (25.0) and glucose (11.1).
The atria were then inserted into silver ring electrodes, the left 
atria being attached with thread to a hook at the bottom end of the 
electrode. The atria were then transferred to a 25ml double­
jacketed organ bath containing Krebs solution at 35°C and gassed with 
95% 02/5% C02 . The paired atria were attached by thread from the 
right atria to a Statham force displacement transducer and placed
under a resting tension of l.Og. Changes in tension of the isolated 
atria were recorded isometrically on a Grass Polygraph (model 79D). 
Under these conditions the atria beat spontaneously at a mean rate of
251 —  4 beats min~*,( n=38) and a mean force of 0.35 — O.Olg. tension.
In some experiments the left atrium alone was inserted into silver 
ring electrodes and subsequently transferred to an organ bath 
whereupon it was placed under l.Qg tension. This preparation did not 
beat spontaneously but could be paced electrically at a constant 
frequency produced by electrical stimulation.
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ii) Spontaneously Beating Paired Atria
The responses of isolated spontaneously beating paired atria to the 
beta^-adrenoceptor agonist, isoprenaline, and the muscarinic 
cholinoceptor agonist, carbachol were examined. Increasing 
concentrations of the respective agonists were added to the organ bath 
to produce a cumulative dose-response. The effect of various 
concentrations of the agonists on the rate of atrial beating was 
examined.
The responses were examined in 3 ways. First, as absolute changes in
the rate of beating caused by addition of the agonist. Secondly, as
the incremental change caused by the specific concentration of 
agonistJ this allows the maximum effect of the agonist to be seen. 
Finally, the results were expressed as a percentage of the maximum 
response of the tissue.
The effects of pretreatment with thyroxine (T^) on the sensitivity of
the atria to these agonists were examined. Thus, responses to these
agonists from control animals and animals pretreated with T^ were 
compared.
Spontaneously-beating paired atria were stimulated electrically by 
field stimulation through silver ring electrodes with a Palmer Square 
Wave stimulator or a Grass S88 stimulator. Field stimulation of atria 
caused the release of transmitters from nerve endings and produced a 
complex mechanical response immediately after cessation of stimulation 
(Fig 1). During stimulation the atria was driven electrically if the 
frequency of stimulation was above the inherent rate of beating. 
Immediately following stimulation the atria produced a complex
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response. First, a negative inotropic response developed which was 
transient and which was rapidly (2-3sec.) superseded by positive 
inotropic and chronotropic responses. The positive component of the 
response was also transient and the tissue returned to pre-stimulation 
control levels. The technique of stimulating spontaneously-beating 
paired atria has been employed previously (Idowu & Zar, 1977) but was 
not fully exploited. These workers confined their efforts to an 
examination of the chronotropic response of the atria. In the present 
study the three components of the post-stimulus response were examined 
and appeared to reflect the release of transmitters during the 
stimulation period. The preparation allowed examination of the 
effects of drugs which act to inhibit or promote the release of the 
transmitters or which inhibit the post-synaptic effects of the 
released transmitters.
Field stimulation-induced inotropic and chronotropic responses were 
measured isometrically following stimulation. The inotropic and 
chronotropic post-stimulus responses occurred at different frequencies 
of stimulation (20 pulses, pulse width 1 m s ,  0.2-20Hz supramaximal 
voltage). The atria were stimulated 2 minutes after the tissue had 
returned to the pre-stimulation control values of rate and force.
The post-stimulus responses were expressed as percentage change above 
or below basal control levels immediately preceding stimulation. 
Comparisons were made between frequency-response curves obtained in 
the absence and presence of drugs.
In addition to the above experiments atria from animals pretreated 
with T^ and reserpine were field stimulated. Comparisons were made 
between responses from such atria and atria from control animals.
37
iii) Paced Atria
The post-synaptic inotropic effect,, of the alpha^-adrenoceptor agonist 
phenylephrine was examined on the paced left atria of the rat in the 
absence and presence of the alpha^-adrenoceptor antagonist prazosin. 
The left atria was stimulated through silver ring electrodes by a 
Palmer Square Wave stimulator at a frequency of 1Hz., 5m s pulse 
width and 1.5 x supramaximal voltage. The experiment was carried out 
in the presence of 5x10 ^ M tetrodotoxin (TTX), which prevented Na+ 
conductance and the production of action potentials in the nerves and 
consequently the release of transmitter and 10-^ M propranolol which 
blocked the myocardial beta-adrenoceptor. This ensured that any 
response produced was solely due to phenylephrine acting on a post- 
synaptic alpha^-adrenoceptor. A cumulative dose-response curve was 
obtained for phenylephrine. The positive inotropic response to each 
dose was allowed to reach a maximum level prior to addition of the 
next dose. Results were expressed as a percentage increase in 
response above control levels. Comparisons were made between the 
effects of phenylephrine on control atria and atria from animals 
pretreated with T^.
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THE FIELD STIMULATION-INDUCED RELEASE OF RADIOACTIVITY FROM ATRIA 
INCUBATED IN [ ^H] -NORADRENALINE AND [14C]-CHOLINE
Adult, male, Wistar rats (250-320g) were stunned and killed by 
exsanguination. The hearts were dissected and the paired atria 
separated from the ventricles. The atria were then transferred to 
0.5ml of Krebs bicarbonate buffer and gassed with a mixture of O2 » 
95%/C02, 5% containing 10jt/Ci of [3H]-NA (500nM 43 Ci mmol”1). Atria 
were incubated in this radioactive solution (30 min., 37°C) and 
inserted into silver ring electrodes, transferred to organ baths (2ml 
capacity) and attached to Statham force displacement transducers 
(resting tension l.Og) to record motor responses isometrically 
(Fig. 2). These atria were continuously superfused with Krebs solution 
(37°C, 4 ml/min, 1.5hr) to remove loosely bound [3H]-NA not taken up 
into the nerves. At the end of this preliminary washing period the 
superfusion was stopped. Atria were field stimulated with a Palmer 
Square Wave stimulator (60 pulses, pulse width lm s , 2Hz, 
supramaximal voltage) every 10 minutes. At 2 minute intervals before 
the first stimulation and between each subsequent stimulation the 
contents of the organ bath were removed and collected in liquid 
scintillation vials, each containing 10ml of Ecoscint (National 
Diagnostics). The organ baths were then filled with fresh Krebs 
solution. Drugs were added to the organ bath at 2 minutes or 10 
minutes prior to stimulation and were dissolved in Krebs solution 
unless otherwise stated. The radioactivity in each scintillation vial 
was counted in a Packard Tri-Carb liquid scintillation counter. Each 
pair of atria was digested in K0H (1ml, 0.5M, 24 hr, 60°C) so that the 
residual radioactivity in the tissue could be determined. All 
radioactive counts were corrected for quenching enabling the counted 
radioactivity to be expressed as disintegrations per minute. The field
Apparatus for Overflow Experiment
Oxygenated Krebs
Pump
Heating
Transducer
to Water 
Heater
Electrode 
Atria—
Collectlng 
Beaker
FIGURE 2. Diagram of apparatus used for overflow experiments.
stimulation—induced release of radioactivity was expressed as 
fractional release. The fractional release value was obtained by 
calculating the d.p.m. produced by field stimulation above that of 
basal release immediately prior to stimulation. This figure was 
subsequently expressed as a fraction of the total amount of 
radioactivity released coupled with that obtained from the digested 
tissue.
The [ H]-NA released into the organ baths during stimulation was 
separated from its metabolites by column chromatography.
In some experiments paired atria were dissected free of the ventricles 
and transferred to 0.5ml of Krebs bicarbonate buffer containing 10 ;iCi 
of [^C]-choline (500nM 43 Ci mmol- )^ and gassed with a mixture of O2 , 
95%/C02» 5%. Atria were incubated in this radioactive solution (60 
mins, 37°C), mounted in silver ring electrodes and placed in organ 
baths as described previously. Incubation of atria with choline 
results in the synthesis of a pool of ACh, contained in nerves, which 
can be released by potassium depolarisation (Wetzel & Brown, 1983,
1985). This study examined the effects of field stimulation on 
release of [^^C]-choline. Occasionally, atria were simultaneously 
incubated in [3H]-NA and [^Cj-choline and the effect of field 
stimulation and drugs on the release of both [ H] and [ qC] were 
examined.
Once the atria had been incubated in [^C]-choline they were 
transferred to 2ml organ baths. As before the atria were superfused 
with Krebs solution (37°C, 4ml/min 2 hrs). This Krebs solution 
included physostigmine (10_6M) and hemicholinium —  3.(10-5M). 
Physostigmine and hemicholinium-3. prevented respectively, enzymatic
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degradation of ACh and re-uptake of choline (Fosbraey & Johnson, 
1980).
At the end of this preliminary washing period the superfusion was 
stopped. Atria were field stimulated with a Palmer Square Wave 
stimulator (525 pulses, pulse width 1 m s ,  5Hz, supramaximal voltage) 
every 10 minutes. At two minute intervals before the first stimulation 
and between each subsequent stimulation the contents of the organ bath 
were collected in scintillation vials containing 10ml Ecoscint. Drugs 
were added to the organ baths and were present throughout the 
stimulation period. None of the drugs employed affected the basal 
release of either [%] or [^C]. As before, the amount of 
radioactivity contained in each sample was determined as was the 
residual radioactivity remaining in the tissue. This enabled the 
fractional release obtained with each stimulation to be calculated.
METABOLISM STUDIES
A metabolite assay (Fig.3) was carried out in order to determine the 
components of the [%] overflow produced from field stimulated atria.
Alumina was treated according to the method of Crout (1961) and washed 
with 0.2M sodium acetate before drying. Dowex 50W x 4 (200-400 mesh) 
was washed several times with 2M NaOH (containing 1% Na-EDTA) at 50°C 
until the supernatant was clear, then washed with H20, 2M HC1, H20 
and, finally, equilibrated with 0.01M HC1. Columns used for 
chromatography were 50mm in diameter and stoppered with cotton wool. 
Acid-activated alumina (200mg) was washed before use with 0.2M sodium
SAMPLE 
(2ml. pH 8*2-84I
EFFLUENT
|pj AEOx (200mg)
I eluate
+  Wash 
Xml 0'2M CHjCOONa 
2mlHJ3
3ml aliquot
vi)
EFFLUENT;
-f- Wash 
2mlH,0
VMA /MOPEG
Wash
3-5ml 0'2M CHJEOOH
2m! aliquot
DOW EX SOW X 4 
lO'Sml, pH h2)
ELUATE
2ml 6M HCl'EtOH 
(hi )
EFFLUENT/
+  Wash 
2mlHt0
NMN DOPEG
M0-2HHCI
ELUATE
(HI)
2mlti0J
Discard
(iv)
3ml 3M HCl
NA DOMA
FIGURE 3. Flow diagram of the chromatographic separation of (^H)-NA 
from Its metabolites. 2 ml samples were applied to the alumina 
columns . The effluent and washings contained COMT metabolites. The 
acetic acid eluate contained the NA and DOPEG. The HCl eluate from 
the alumina contained DOMA. The COHT metabolites were separated by a 
DOWEX-50W x column into VMA/MOPEG and NMN. The NA-DOPEG fraction 
was also separated by a DOWEX-50W x H column into DOPEG and NA.
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acetate (pH 8.2). Dowex columns were filled to a height of 1.5cm 
(0.5ml) with resin and washed with 2 ml H20.
10 p.g of unlabelled NA and of each NA metabolite were added as carrier 
to each sample. The pH of the samples was adjusted to 8.2-8.4 with 
(0.5m) Tris buffer (pH8.2). The samples were then immediately placed 
in the columns. After addition, the column was washed through with a 
further 1ml of 0.2M sodium acetate and 2 ml H20. The effluent and 
washing contained the 0-methylated metabolites 3-methoxy-4- 
hydroxyphenylglycol (MOPEG), 3-methoxy-4-hydroxymandelic acid (VMA) 
and normetanephrine (NMN).
The [%]-NA and [^H]- 3,4-dihydroxygphenylglycol (DOPEG) fraction was 
then eluted with 3.5ml 0.2M acetic acid. After washing the column 
with 4ml 0.5M acetic acid, which elutes approximately 5% of both NA 
and DOPEG, the deaminated acid, 3,4 dihydroxymandelic acid (DOMA) was 
eluted with 3ml 0.2M HCl.
[^H]-NA was separated from the [**H]-D0PEG by means of the strong 
cation exchange resin Dowex 50W x 4. 2ml of the [^H]-NA/[^H]-DOPEG 
fraction was poured onto the Dowex column and washed through with 2ml 
H20. The effluent and washings contained DOPEG. After washing with a 
further 2ml H20, which was discarded, the NA was eluted with 3ml 3M 
HCl.
The 0-methylated fraction was separated using Dowex-50W x 4 columns. 
The 0-methylated metabolites (VMA and MOPEG) passed through the column 
and were collected in the effluent. NMN was retained by the Dowex and 
subsequently eluted with 2ml 6M HCl/ethanol (1:1 v/v).
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lml of each separated fraction was added to 10ml of Ecoscint in a 
counting vial and radioactivity was measured in a liquid scintillation 
counter.
The method of separation was essentially that of Graefe et al (1973) 
and Nicol (1975) with the following modifications. Volumes of eluates 
were increased so that aliquots could be taken for counting before 
column separation. This allowed corrections for recovery to be made 
in each sample. The volume of 0.2m acetic acid used to elute the 
NA/DOPEG fraction from the alumina column was increased from 2ml to 
3.5ml and the 0.2M HCl used for elution of [3H]-D0MA was increased 
from 2.5ml to 3ml. The concentration of HCl required to elute [3H]-NA 
was increased from 2M to 3M and the volume from 2ml to 3ml. These 
alterations were made to ensure complete recovery of [3H]-NA.
Calculation of Metabolism Results
The amount of radioactivity appearing in each of the metabolite 
samples was compared to that in the sample before separation to give 
an indication of the recovery and efficiency of each column. The 
recovery for the alumina column was 85.3- 2.3% (n=8) and for the Dowex 
columns 95.3- 3.9% (n=8) and 93.7- 4.7% (n=8) respectively.
The amount of [3H]-NA and [3H]-metabolites present in the pre­
stimulation sample were subtracted from the amount in each sample
O
obtained after field stimulation.[ H]-NA and its metabolites were
O
expressed as a percentage of the total [ H] present in the samples. 
Results were expressed as mean —  standard error of the mean. 
Significance was assessed by student’s t—test.
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IN VIVO EXPERIMENTS
i) Anaesthetised Rats
Male Wistar rats (250-300g) were anaesthetised with pentobarbitone 
(60mg/kg, i. p.). In each animal the trachea was cannulated to allow 
respiration to be maintained artificially with a Palmer pump. The 
left carotid artery was cannulated and blood pressure (B.P.) recorded 
using a Statham pressure transducer. In addition, the arterial pulse 
was used to trigger a Devices Instantaneous Ratemeter for measurement 
of heart rate (H.R.). Both variables were recorded on a Devices M2 
physiological recorder. The left femoral vein was cannulated to allow 
administration of drugs. The right branch of the vagus nerve was 
carefully separated from the carotid artery and was placed over 
bipolar silver electrodes which were connected to a Palmer Square Wave 
stimulator. The vagus nerve was stimulated at various frequencies at 
a pulse width of 0.1ms and at supramaximal voltage. Such stimulation 
caused a depressor effect on both the H.R. and B.P. The effect of 
various drugs on the chronotropic response to vagal stimulation was 
examined.
ii) Pithed Rats
Animals were pithed according to the method of Gillespie et al, 1970. 
Male, Wistar rats were anaesthetised with pentobarbitone (60mg/kg 
i.p.) and respired artificially through a tracheal cannula. Rats were 
pithed by inserting a short steel tube through the orbit and foramen 
magnum into the spinal canal. Through this trocar was passed a fine 
steel wire contained in a teflon tube and this was pushed down to the 
sdcrdl end of the spinal canal. A separate steel rod, inserted behind 
the skull and pushed down between the vertebral column and the skin 
acted as an indifferent electrode. The steel rod extruding from the
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spinal canal and the indifferent electrode were connected to a Palmer 
Square Wave stimulator. The temperature of the pithed animal was 
maintained at approximately 37°C by radiant heat. As with the 
anaesthetised rats the left carotid artery was cannulated in order to 
record B.P. and H.R. and the left femoral vein cannulated to permit 
administration of drugs. Again, as before, the right branch of the 
vagus was exposed and placed over bipolar silver electrodes connected 
to a Palmer Square Wave stimulator. The pithed animal was left for 60 
minutes to allow H.R. and B.P. to stabilise. After this period 
tubocurarine was administered (lmg/kg, i.v.) to prevent electrical 
stimulation-induced contractions of voluntary muscle interfering with 
the recordings of B.P. and H.R.
The length of the stimulating electrode extruding from the shielding 
teflon tube could be varied but was maintained at 1cm. This 1cm length 
was positioned at Cy-T^ in the spinal canal, the position of the 
sympathetic cardioaccelerator nerves. Stimulation via the spinal 
electrode at this level at various frequencies, at 0.03ms. pulse-width 
and at supramaximal voltage produced increases in H.R. with very small 
changes in B.P. Stimulation of the exposed vagus nerve at various 
frequencies, 0.1ms pulse width and at supramaximal voltage produced a 
fall in H.R. at low frequencies (5Hz) of stimulation. At high 
frequencies of stimulation (10Hz) there was a more complex, biphasic 
response, which consisted of a fall followed by a rise in H.R. This 
preparation allowed independent or simultaneous stimulation of the 
cardioaccelerator and vagus nerves. The effect of various drugs on 
1^ ^ 0 chronotropic responses to stimulation of these nerves was 
examined. Drug concentrations were administered and are expressed as
Pg Kg"1.
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RADIOIMMONK ASSAY OF FREE SERUM THYROXINE T.FVELS
Blood samples were collected from control and pretreated rats. 
Radioimmune assay of serum allowed the effectiveness of the
pretreatment to be monitored. An Amersham Amerlex T^ RIA kit (IM3050) 
was used for the immune assay of free in the serum obtained. This 
method is dependent upon the competition between and free
in the serum for a limited number of binding sites on a T^—specific 
antibody. The proportion of the [^^Ij-T^ bound to the antibody is 
inversely related to the concentration of free T^ present in the 
serum. Standards (containing known amounts of T^) and the serum 
samples were mixed with both and T^-specific antibody
suspension and then allowed to stand for 60 min at 37^C. 
Centrifugation (2000 x g, 5min, room temperature) produced a pellet of
i o r
antibody containing bound [ I]-T^ and T^ beneath a liquid
supernatant. The supernatant was discarded and the pellet was placed
in a gamma counter to record the level of radiation. A standard curve
1 2*5was constructed showing the concentration of free T^ versus [ I ]  
counts. From this standard curve it was possible to calculate the 
amount of free T^ in the serum from control and treated rats.
STATISTICS
Each response is expressed as a mean with a standard error of the mean 
(x - S. E. mean). To compare results, the student's t-test,or where 
appropriate,the paired t-test was used. Levels of significance:
*0.05>p>0.01; ** 0.01>p>0.001; *** p<0.001.
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DRUGS USED
The drugs used during the project were acetylcholine chloride (Sigma), 
L-ascorbic acid (Sigma), atropine sulphate (Sigma), 8-bromo-cyclic 
3 1,5'-adenosine monophosphate (Sigma), 8-bromo-cyclic 3',5'-guanosine 
monophosphate (Sigma), carbamylcholine chloride (Sigma), [methyl-^C]- 
choline (Amersham), clonidine hydrochloride (Sigma), desipramine 
hydrochloride (Sigma), dL-3,4-dihydroxymandelic acid (Sigma), dL-3,4- 
dihydroxyphenylglycol (Sigma), dimethylsulphoxide (Sigma), forskolin 
(Sigma), guanethidine sulphate (Ciba), dL-4-hydroxy-3-methoxymandelic 
acid (Sigma), bis-4-hydroxy-3-methyoxyphenylglycol (Sigma), 3- 
isobutyl-l-methylxanthine (Sigma), isoprenaline sulphate (Sigma), L-
Q
[7,8- H] noradrenaline (Amersham), L-noradrenaline bitartrate (Koch- 
Light), dl-normetanephrine hydrochloride (Sigma), 17 beta-oestradiol 
(Sigma), pentobarbitone sodium (May and Baker), phenoxybenzamine 
hydrochloride (Smith Kline and French), phentolamine mesylate (Ciba), 
trans-2-phenylcyclopropylamine hydrochloride (Sigma), phenylephrine 
hydrochloride (Sigma), prazosin hydrochloride (Pfizer), propranolol 
hydrochloride (ICI), reserpine (Sigma)j sodium nitroprusside (Analar), 
tetrodotoxin (Boehringer), L-thyroxine (Sigma), d-tubocurarine 
(Wellcome) and yohimbine hydrochloride (Sigma).
The drugs were prepared in Krebs bicarbonate buffer solution unless 
otherwise stated.
L-[7,8-3H]-noradrenaline (10-48Ci mmol”1) supplied in 0.02M acetic 
acid: ethanol (9:1 v/v), was resuspended in distilled water containing 
ascorbic acid (5.7 x 10“3M) to prevent breakdown of the amine.
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Forskolin was dissolved in dimethylsulphoxide (DMSO). DMSO was never 
added in a concentration greater than 1%.
Reserpine was dissolved in glacial acetic acid (0.3ml, 17.5M) and 
diluted with distilled water.
Phenoxybenzamine and 17, beta-oestradiol were made up in absolute 
alcohol but were never added in volumes greater than 0.25 ul/ml of 
Krebs solution.
Pertussis toxin was dissolved in 50mM Tris-IM NaCL pH8 buffer.
ANIMAL PRETREATMENTS
(i) Pertussis Toxin
Pertussis toxin was administered to rats intravenously in a dose of 
10 Jig/kg body weight contained in 0.1-0.4ml of vehicle. Control rats 
were injected with a similar volume of vehicle. Experiments were 
carried out 72 hours after injection of the vehicle or pertussis 
toxin.(i.v. tail vein).
(ii) Reserpine
Reserpine was administered to rats intraperitoneally in a dose of 
lmg/kg body weight contained in 0.3-0.6ml of vehicle. Control rats 
were injected with a similar volume of vehicle. Animals were treated 
with reserpine or vehicle for 3 consecutive days and on the fourth day 
were killed.
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(iii) L-Thyroxine
Thyroxine was administered orally in the drinking water. Preliminary 
studies indicated that a 250g. rat drinks 50ml of water per day. 
Thyroxine was added to the water to give a solution of 25mg/litre. 
This gave each rat a dose of 5mg/kg/day. The rats were treated for 14 
days before being used.
RESULTS
PART I
RESPONSES OF THE HEART RATE IH ANAESTHETISED AND PITHED RATS TO VAGAL 
STIMULATION AND CARPIO-ACCELERATOR NERVE STIMULATION, AND THE EFFECTS 
OF DRUG ADMINISTRATION ON THESE RESPONSES
Electrical stimulation of the vagus nerve produced a frequency- 
dependent decrease in heart rate in both pithed and anaesthetised 
rats. The negative chronotropic response to vagal stimulation was 
greater in the anaesthetised rat than in the pithed rat (Fig. 4).
Electrical stimulation of the cardio-accelerator nerves in the spinal 
column at C7-T1 resulted in a frequency-dependent increase in heart 
rate (Fig. 5).
Intravenous (i.v) administration of propranolol (50 jig Kg *) abolished 
the positive chronotropic response of the heart evoked by cardio- 
accelerator nerve stimulation or by administration of NA 
(0.1 jig Kg”1). Atropine (50 jig Kg”1) abolished the negative 
chronotropic response of the heart evoked by vagal stimulation or by 
administration of acetylcholine (0.6 p.g Kg 1) (Table 1).
When the vagus nerve was stimulated during stimulation of the cardio­
accelerator nerves the negative chronotropic response to vagal 
stimulation was enhanced (Figs. 6, 7).
In the pithed rat, administration of NA (0.1 i^g Kg 1) resulted in an 
increase in heart rate. Stimulation of the vagus nerve in the presence 
of NA resulted in an enhanced bradycardia (Figs. 8, 9).
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FIGURE A. Frequency response curve showing the effects of 
stimulation of the vagus nerve on heart rate (Beats m i n ” *)
in situ in anaesthetised (0- - -0) and pithed (t------• ) rats.
Each point is the mean (— S.E. mean) of A observations. 
Stimulation results in a decrease in heart rate.
** 0 . 0 1 > P > 0 .001, ***P<0.001.
P.R.: Resting heart rate: 200 beats m i n ” *.
A .R .: Resting heart rate: 350 beats m i n ” *.
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FIGURE 5. Frequency response curve showing the effects of 
stimulation of the cardio-accelarator nerves via a spinal 
electrode on heart rate in the pithed rat.
Stimulation results in an increase!in heart rate.
Each point is the mean (—  S.E. mean) of 6 observations.
Table 1. Effect of atropine and propranolol on the chronotropic
responses of the heart to nerve stimulation, ACh and NA.
Changes in heart rate —A B P M  (— S.E. mean)
Treatment Control 50^LgKg”  ^ 50^igKg_ ^
Atropine Propranolol
a) Pithed rat
Cardio-accelerator
nerve stimulation +34.8-4.2 - 0.0-0***
(2Hz x 30s)
0.1 pgK g ” 1
Noradrenaline +23.5—0.8 - 0.0-0***
b) Anaesthetised rat
Vagal nerve
stimulation -64— 7.2 0.0— 0***
(5Hz x 10s)
0.6 p g K g -1 ACh ” 274— 25 0.0*0***
Each value is the mean of { 6 observations.
***p<0.001 for comparison with control prior to drug addition.
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Figure 6. Recording of the response of the heart rate in a 
pithed rat to vagal stimulation (5Hz x 5s) alone and against 
a background of increased heart rate produced by stimulation 
of the cardio-accelerator nerves (2Hz x 30s) in the spinal 
column. The response to vagal stimulation was enhanced by 
the concommitant stimulation of the cardio-accelerator 
n e r v e s .
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FIGURE 7. Effect on heart rate produced by stimulating the 
vagus nerve (5Hz x 5s), in the pithed rat, alone and against 
a background of cardio-accelerator nerve stimulation 
(2Hz x 30s). The open histogram shows the effect on heart 
rate produced by vagal stimulation alone and the diagonal 
striped histogram shows the effect of vagal stimulation 
against a background of cardio-accelerator nerve 
stimulation. Each column represents the mean (—  S.E. mean) 
of 5 observations. ** 0.01> P > 0 .001.
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FIGURE 8. Recording of the response of the heart rate in a 
pithed rat to vagal stimulation (5Hz x 5s) alone and against 
a background of increased heart rate produced by intravenous 
(i.v.) administration of exogenous NA. The response to vagal 
stimulation was enhanced in the presence of NA.
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FIGURE 9. Effects of vagal stimulation and exogenous NA 
alone and combined on heart rate in the pithed rat. The 
upper stippled diagonal striped histogram shows the effec 
of NA on heart rate. The lower diagonal striped histogran 
shows the inhibitory effect of vagal stimulation on heart 
rate. The lower stippled vertical striped histogram shows 
the effect of vagal stimulation against the raised heart 
rate produced by exogenous NA. Each column represents the 
mean (—  S.E. mean) of 4 observations. * 0.05>p>0.01.
Clonidine (5 pg Kg *) inhibited the response evoked by electrical 
stimulation of the cardio-accelerator nerves in the spinal cord. 
Yohimbine (100 pg Kg-*) reversed the inhibitory effect of clonidine 
(Fig. 10). In contrast, neither clonidine (5 pg Kg-*) nor yohimbine 
(100 pg Kg *) affected the increase in heart rate obtained with 
exogenous NA (0.1 pg Kg-1) (Fig. 11).
In the pithed rat, clonidine (5 pg Kg-*) attenuated the inhibitory 
effect on heart rate obtained by electrical stimulation of the vagus. 
Yohimbine (100 pg Kg""*) did not completely reverse the effect of 
clonidine (Figs. 12, 13).
In the anaesthetised rat, clonidine (5 pg Kg-*) inhibited the negative 
chronotropic response obtained by electrical stimulation of the vagus. 
Yohimbine (100 pg Kg-*) partially reversed the attenuating effect of 
clonidine (Fig. 14).
In the anaesthetised rat, phenylephrine (1 pg Kg-*) inhibited the 
negative chronotropic response obtained by electrical stimulation of 
the vagus. Prazosin (100 pg Kg-*) reversed the attenuating effect of 
phenylephrine (Fig 15).
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FIGURE 10. Inhibitory effect of clonidine and reversal by 
yohimbine on the response of the heart rate to c a r d i o ­
accelerator nerve stimulation (2Hz x 30s) in the pithed rat. 
The open histogram shows that stimulation of the cardio- 
accelarator nerves results in an increase in heart rate. The 
diagonal striped histogram shows the inhibitory effect of 
clonidine on this response. The vertical striped histogram 
shows that yohimbine can reverse the inhibitory effects of 
clonidine. Each column represents the mean (i S.E. mean) of 
4 observations. * 0.05>P>0.01.
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FIGURE 11. Effect of clonidine and yohimbine on the response 
of the heart rate to exogenous NA in the pithed rat. The 
open histogram shows the control response produced by NA.
The diagonal striped histogram shows the lack of effect of 
clonidine on this response. The vertical striped histogram 
shows the lack of effect of yohimbine on the response to NA 
in the presence of clonidine. Each column represents the 
mean (- S.E. mean) of A observations.
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FIGURE 12. Recording of the effects of vagal stimulation 
(10Hz x 10s) on heart rate in the pithed rat and the effects 
of clonidine and yohimbine on this response. Stimulation of 
the vagus resulted in a decrease in heart rate. 
Administration of clonidine attenuated this response and 
further administration of yohimbine reversed the inhibitory 
effect of clonidine.
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FIGURE 13. Inhibitory effect of clonidine on the response of 
the heart rate to vagal stimulation (10Hz x 10s) in the 
pithed rat. The open histogram shows that stimulation of the 
vagus nerve results in a decrease in heart rate. The 
diagonal striped histogram shows the inhibitory effect of 
clonidine on this response. The vertical striped histogram 
shows that yohimbine did not significantly reverse the 
inhibitory effect of clonidine. Each column represents the 
mean (~ S.E. mean) of 4 observations. * 0.05>P>0.01.
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FIGURE 1A. Inhibitory effect of clonidine and reversal by 
yohimbine on the response of the heart rate to vagal 
stimulation (5Hz x 10s) in the anaesthetised rat. The open 
histogram shows that stimulation of the vagus nerve results 
in a decrease in heart rate. The diagonal striped histogram 
shows the inhibitory effect of clonidine on this response. 
The vertical striped histogram shows that yohimbine can 
reverse the inhibitory effect of clonidine. Each column 
represents the mean (—  S.E. mean) of A observations.
* 0.0 5 > P > 0 .01.
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FIGURE 15. Inhibitory effect of phenylephrine and 
reversal by prazosin on the response of the heart rate 
to vagal stimulation (5Hz x 10s) in the anaesthetised 
rat. The open histogram shows that stimulation of the 
vagus nerve results in a decrease in heart rate. The 
diagonal striped histogram shows the inhibitory effect 
of phenylephrine on this response. The vertical striped 
histogram shows that prazosin can reverse the 
inhibitory effect of phenylephrine. Each column 
represents the mean (~ S.E. mean) of A observations.
* 0.05> P > 0 .0 1 , ** 0 . 0 1 > P > 0 . 0 0 1 .
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PART II
THE EFFECT OF DRUGS OH THE POST-STIMULUS RESPONSE OF THE SPONTANEOUSLY 
BEATING PAIRED ATRIA OF THE RAT
Field stimulation of isolated spontaneously beating paired atria 
resulted in a post-stimulus response that consisted of a negative 
inotropic component, a positive chronotropic component and a positive 
inotropic component (Fig. 1).
Field stimulation at increasing frequencies resulted in a frequency- 
dependent increase in the force of contraction of the atria. 
Production of several frequency response curves in the same 
preparation did not affect the reproducibility of the response 
(Fig. 16).
Field stimulation also resulted in a negative inotropic response. This 
response reached a maximum at 6—8Hz and was unaffected by propranolol 
(10“6 M) (Fig. 17). The response was, however, abolished by atropine.
A small positive chronotropic response was obtained by field 
stimulating isolated spontaneously beating paired atria. This 
component was unaffected by atropine (1CT6 M) (Fig, 18). This response 
was, however, abolished by propranolol (10“7 M) amd guanethidine
(10"6 M).
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FIGURE 16. Frequency response relationship at 
increasing frequencies of stimulation of the positive 
inotropic component of the post-stimulus response of 
the spontaneously beating paired atria of the rat. The 
frequency response curve was produced several times to 
ensure repeated stimulation did not affect the
reproducibility. Frequency response curve 1, (0----- 0),
frequency response curve 2, (A A), frequency response
curve 3, (>• ’ ♦) . Repeated production of frequency
response curves did not affect the reproducibility of 
the response. Each point is the mean (i S.E. mean) of 
(C 4 observations.
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FIGURE 17. Frequency response relationship at
increasing frequencies of stimulation of the negative
inotropic component of the post-stimulus response of
the spontaneously beating paired atria of the rat.
Frequency response curves were produced in the absence
— f)(9----- • ) and in the presence of propranolol (10 M)
(0----- 0). Propranolol did not affect this response of
the atria to field stimulation. Each point represents 
the mean (-^  S.E. mean) of 6 observations.
c  100~i
o
i2 2 80-
C L  3  
O  E  
4—' — H
° 4_’ 60 -C  CO U U
CD
O 4—*
4—
CD Control(n-
_ CD 
CO
^  §  20-  
g
CD Atropine(n=6)
Frequency Hz
Figure 18. Frequency response relationship at 
increasing frequencies of stimulation of the 
chronotropic component of the post-stimulus response of 
the spontaneously beating paired atria of the rat. 
Frequency response curves were produced in the absence
(0----0) and presence of atropine (10- ^ M) (■— — —■).
Atropine did not affect this response of the atria to 
field stimulation. Each point represents the mean 
(—  S.E. mean) of { 6 observations.
Atropine (10 ** M) potentiated the positive inotropic component of the 
post-stimulus response of the atria (Fig. 19).
The positive inotropic post-stimulus response was inhibited by 
propranolol (10”** M) and guanethidine (10”** M) (Fig. 20).
Phenoxybenzamine (10”** M) potentiated the positive component of the 
post-stimulus response of the atria (Fig. 21).
Reserpine abolished the positive components of the post-stimulus 
response of the atria. ______________ ___________
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FIGURE 19. Effect of atropine on the positive inotropic 
component of the post-stimulus response of the atria. 
Frequency response curves were produced in the absence
(0----- 0) and presence (•------ 1) of atropine (10- ^ M) .
Atropine potentiated this response of the atria 
following field stimulation. Each point represents the 
mean of (- S.E. mean) of £ 6 observations.
* 0.05>P>0.01, ** 0.01>P>0.001, *** P<0.001.
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FIGURE 20. Effect of propranolol and guanethidine on the 
positive inotropic component of the post-stimulus 
response of the atria. Frequency response curves were
produced in the absence (0----- 0) and presence of
propranolol (10~^ M) (□---- □) and in the presence of
guanethidine (10~^ M) (•----- • ). Both propranolol and
guanethidine inhibited this response of the atria 
following field stimulation. Each point is the mean 
(- S.E. mean) of £ 7 observations. *** P<0.001.
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Figure 21. Effect of phenoxybenzamine on the positive 
inotropic component of the post-stimulus response of 
the atria. Frequency response curves were produced in
the absence (0----- 0) and presence (A A) of
phenoxybenzamine (10-  ^ M ) . Phenoxybenzamine 
potentiated this response of the atria following 
field stimulation. Each point is the mean 
(—  S.E. mean) of ^ 6 obsevations.
** 0.01>P>0.001, *** p< 0.001.
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Clonidine (10 ^ M) did not affect the positive inotropic component of 
the post-stimulus response of the atria. Yohimbine (10 ^ M), however, 
potentiated this response in the presence of clonidine (Fig. 22).
In the presence of atropine (10”^ M), clonidine (10-^ M) did inhibit 
the positive inotropic component of the post-stimulus response of the 
atria (Fig. 23).
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Figure 22. Effect of clonidine and yohimbine on the 
positive inotropic component of the post-stimulus 
response of the atria. Frequency response curves were
produced in the absence (0----- 0) and presence of
clonidine (10” ^ M) (•----- •) and in the presence of
yohimbine (10"”^ M) (•— — •). Clonidine did not affect 
this response of the atria. Yohimbine, however, 
potentiated the response in the presence of 
clonidine. Each point is the mean (— S.E. mean) of 
fc 7 obsevations.
* 0. 0 5 > P > 0 .01, ** 0 . 0 1 > P > 0 .001, *** PC0.001.
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FIGURE 23. Effect of clonidine in the presence of
atropine on the positive component of the post-stimulus
response of the atria. Frequency response curves were
— 6produced in the presence of atropine (10 M) (•— —— #) 
and in the presence of atropine an-d clonidine (10” ^ M)
(0----- 0). In the presence of atropine, clonidine
inhibited this responseof the atria. Each point is the 
mean (—  S.E. mean) of { 5 observations.
* 0.05>P>0.01, ** 0.01>P>0.001, *** p<0.001.
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PART III
EFFECTS OF FIELD STDPJLATIOH OH THE OVERFLOW OF %  FROM ATRIA 
PREVIOUSLY INCUBATED IN [^Hj~NA, AMD THE EFFECTS OF DRUGS ON THIS 
OVERFLOW
Electrical stimulation of atria increased the amount of radioactivity 
released into the Krebs solution in the organ bath. Collections of 
Krebs solution between stimulations contained only low levels of 
radioactivity. Consecutive stimulations at regular intervals (10 min) 
resulted in reproducible increases in the amount of radioactivity 
evoked by field stimulation (Fig. 24).
Chromatographic separation of [3H]-NA from its metabolites showed that 
field stimulation increased the overflow of [ H]—NA. Whereas only 13% 
of the spontaneous H overflow was recovered as [ H]-NA, almost 80% of 
the 3H radioactivity released into the bathing solution during field 
stimulation was [^H]-NA (Table 2).
Tetrodotoxin (5xl0”9 M - 5xlO"6 M) inhibited the overflow of 
radioactivity from atria in a dose-dependent manner (Fig. 25).
3H overflow
Fractional release 
,*10"3 ^
2.0-
76532
Controls [repeated stimulation]
FIGURE 24. Effect of 7 consecutive stimulations at a 
frequency of 2Hz for a period of 30 sec on ttie release
o
from atria previously incubated in [ H]-NA. Each 
column represents the mean (*■— S.E. mean) of 7 
obse r v a t i o n s .
Table 2. Percentage of (^H)-NA and its (^H)-metabolites in Krebs solution 
bathing isolated, field stimulated atria
/ + \ Mean Percentage (- S.E. Mean;
Compound of H Released
Before stimulation NA 13.2 - 0.8
DOPEG 25.3 - 6.3
OMDA 28.0 - 2.5
NMN 12.9 - 2.1
DOMA 20.6 - 2.6
After stimulation NA 78.2 - 3.1 ***
DOPEG 3.0 - 0.2 **
OMDA 3.0 - 1.2 **
NMN 9.2 - 3.1 NS
DOMA 6.6 - 2.7 **
NA noradrenaline
DOPEG 3 ,4-dihydroxyphenyl glycol
OMDA O-methylated deaminated metabolites
NMN normetanephrine
DOMA 3 ,4-dihydroxymandelic acid
Each value is the mean of  ^5 observations.
** 0.01>P>0.001, *** P<0.001.
For comparison between corresponding values measured before and after
s timulation.
1.5-
io 1.0
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5x10“° 5x10 5x10
Tetrodotoxln
FIGURE 25. Effect of tetrodotoxin on field stimulation-
O
evoked overflow of H m  a t n a .  The open histograms show 
successive control responses prior to drug addition. The 
succeeding 4 shaded histograms show the inhibitory effect 
of tetrodotoxin added in increasing concentrations 
(5x10*"^ M - 5x10”  ^ M) in the same experiments. Each 
column represents the mean (—  S.E. mean) of' 4 
obser v a t i o n s .
** 0.01>P>0.001 for comparison with control prior to drug 
add i t i o n .
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Atropine and yohimbine (10 8 M- 10 "* M) potentiated the overflow of 8H 
from atria. The combined effects of atropine and yohimbine at 10 ^ M
were additive (Fig. 26). The ability of yohimbine (10”8 M - 10”5 M) to
3 -Apotentiate H overflow was enhanced in the presence of 10 M atropine
(Fig 27).
Clonidine (10 8 M - 10 8 M) inhibited the stimulation-evoked overflow 
3of H from atria in a dose-dependent manner (Fig. 28).
_o
Acetylcholine (10 M) potentiated the overflow of radioactivity from 
atria. In the same experiments acetylcholine (10”  ^ M - 10”8 M)
inhibited the overflow of radioactivity in a dose-dependent manner 
(Fig. 29).
H overflow was potentiated by treatment with a combination of
tranylcypromine (10”'* M), desmethylimipramine (10”"* M) and 17,16 -  
oestradiol (10”"* M), which block respectively monoamine oxidase and 
the neuronal and extraneuronal uptake of NA (Figs. 30, 31). The
_ C  9
ability of clonidine (10 M) to inhibit H overflow was retained in
the presence of these blocking drugs (Fig. 30). The ability of
yohimbine (10”'* M) to potentiate 8H overflow was also retained in the 
presence of the blocking drugs (Fig. 31).
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FIGURE 26. Effect of atropine and yohimbine in the 
presence of atropine on the stimulation-evoked release 
of H in atria. The open histograms show successive 
control responses prior to drug addition. The succeeding 
2 diagonal striped histograms show the potentiating 
effect of atropine (10”  ^ M) and the final 2 shaded 
histograms show the further potentiating effect of 
yohimbine (10  ^ M) in the presence of
atropine (10  ^ M ) . Each column represents the mean (i 
S.E. mean) of 4 observations.
* 0.05>P>0.01 for comparison with control prior to 
atropine addition and for comparison with atropine prior 
to yohimbine addition.
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FIGURE 27. Dose %-response curves showing the effects of
atropine (•----• ), yohimbine (D □) and yohimbine in the
presence of atropine (10 ^ M) (0----- 0) on the
stimulation-evoked overflow of H from atria. Asterisks 
indicate a significant difference between yohimbine and 
yohimbine in the presence of atropine. Each point is the 
mean (—  S.E. mean) of £ 5 observations.
** 0.0 1 > P > 0 .001, ***P<0.001.
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Figure 28. Effect of clonidine on field stimulation-
O
evoked overflow of H in atria. The diagonal striped 
histograms show successive control responses prior to 
drug addition. The succeeding 4 stippled histograms show 
the inhibitory effect of clonidine added in increasing 
concentrations (10“ 8 M - 10"5 M) in the same 
experiments. Each column represents the mean 
(—  S.E. mean) of ^ 4 observations. * 0.05>P>0.01.
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FIGURE 29. Effects of ACh on field stimulation-evoked
overflow of H in atria. The open histograms show
successive control responses prior to drug addition. The
succeeding 4 diagonal striped histograms show the
— ft
potentiating effect (10 M) and inhibitory effect
(10“ 7 M - 10 M) of ACh in the same experiments.
Each column represents the mean (— S.E. mean) of 4 
observat i o n s .
* 0.05>P>0.01, ** 0.01>P>0.001 for comparison with 
control prior to drug addition.
* * *
o
2
10 5M 10 5M 10 5M BlockersC c
Blockers 10 Clonidine 
— 6
FIGURE 30. Effect of clonidine (10 M) in the presence
of 10"5 M tranylcypromine, d e s m e t h y 1imipramine and 1 7 , —
3
oestradiol on field stimulation-evoked overflow of H
in atria. The open histograms show successive control
responses prior to drug addition. The 2 diagonal
striped histograms show the significant potentiating 
— 5effect of 10 M tranylcypromine, d e s m e t h y 1 imipramine 
and 17 ,/3— oes tr ad io 1 on this response. The 2 stippled 
diagonal striped histograms show the significant 
inhibitory effect of clonidine in the presence of 
tranylcypromine, desmethylimipramine and 17,j0 — 
oestradiol. Each column represents the mean (—  S.E. 
mean) of { 4 observations. *** P<0.001.
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FIGURE 31. Effect of yohimbine (10- ^ M) in the presence of 
10~-*M tranylcypromine, desme thy limipramine and 17 , (3 ~ 
oestradiol on field stimulation-evoked overflow of in 
atria. The open histograms show successive control 
responses prior to drug addition. The 2 diagonal striped 
histograms show the potentiating effect of
tranylcypromine, desme thylimipr amine and 1 7 ,/3— oe s t r ad io 1. 
The 2 vertical striped histograms show the potentiating 
effect of yohimbine in the presence of tranylcypromine, 
desmethylimipramine and 1 7 , (3— oe s tr ad io 1 . Each column 
represents the mean (—  S.E. mean) of 4 observations.
* 0 .05>P>0.01, ** 0.01>P>0.001 .
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PART IV
EFFECT OF FIELD STIMULATION OH THE OVERFLOW OF **C ASP 3H FROM ATRIA
PREVIOUSLY INCOBATED IN [14C]-CHOLINE AND [3H]~NA, AND THE EFFECTS OF
DRUGS OH THIS OVERFLOW
1A 3Electrical stimulation of atria increased the amount of C and H 
released into the Krebs solution in the organ bath. Collections of
the bathing solution between stimulations produced only low levels of
and 3H. Consecutive stimulations at regular intervals (10 min)
resulted in a decreasing level of ^ C  and 3H overflow evoked by field
stimulation (Fig. 32).
Tetrodotoxin (5 x 10-6 M) inhibited the overflow of 1Z*C from atria
previously incubated in [^C]-choline (Fig. 33).
Clonidine (10“5 M) and acetylcholine (10-5 M) inhibited the
1 / O
simultaneous stimulation-evoked release of C and H (Fig. 34). 
Yohimbine (IO”5 M) and atropine (1(T6 M) potentiated the simultaneous
1 I O
stimulation-evoked release of C and H (Fig. 35).
Prazosin (10~^ M) potentiated the stimulation-evoked release of H 
(Fig. 36) but not that of (Fig. 37) in the same experiments.
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FIGURE 32. The top panel shows the effect of 6 consecutive 
stimulations at a frequency of 5Hz for 105 sec on the 
release of from atria previously incubated in [*^C]-
choline. Each column represents the mean (i S.E. mean) of 
6 observations. The lower panel shows the effect of the
O
same stimulations on the simultaneous release of H from
O
the same atria also incubated in [ H]-NA. Each column 
represents the mean (i S.E. mean) of 6 observations.
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FIGURE 33. Effect of tetrodotoxin on the field
stimulation-induced overflow of in atria. The first
three open histograms show control responses prior to
drug addition. The first shaded histogram shows the
inhibitory effects of tetrodotoxin (5 x 10”  ^ M) on this
response. The next open histogram is a control response
and the inhibitory effect of tetrodotoxin is reversed.
The final shaded histogram shows again the inhibitory
effect of tetrodotoxin (5 x 10  ^ M ) . Each column
represents the mean ( ~  S.E. mean) of 6 observations.
*** P<0.001 for comparison with control prior to drug
addition.
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FIGURE 34. Effect of clonidine (10 5 M) and ACh (IO-5 M) 
on the field stimulation-induced overflow of (top
panel) and H (lower panel) in atria. The first three 
open histograms show control responses prior to drug 
addition. The first shaded histogram shows the inhibitory 
effect of clonidine on the overflow of both and ^H.
The next open histogram is a control response and the 
inhibitory effect of clonidine is reversed. The final 
diagonal striped histogram shows the inhibitory effect of 
ACh on the overflow of both and . Each column
represents the mean (—  S.E. mean) of 6 observations.
* 0.05> P > 0 .01, ** 0.0 1 > P > 0 .001, *** P<0.001 for 
comparison with control prior to drug addition .
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FIGURE 35. Effect of yohimbine (10-  ^ M) and atropine 
(10“ 6 M) on the field stimulation-induced overflow of 
(top panel) and H (lower panel) in atria. The first 
three open histograms show control responses prior to 
drug addition. The first shaded histogram shows the 
potentiating effect of yohimbine on the overflow of both 
and ^H. The next open histogram is a control response 
and the potentiating effect of yohimbine is reversed. The 
final diagonal striped histogram shows the potentiating 
effect of atropine on the overflow of both and ^H.
Each column represents the mean (—  S.E. mean) of 4 
observations.
* .05>P>0.01, ** 0.01>P>0.001 for comparison with
control prior to drug addition.
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FIGURE 36. Effect of prazosin (10  ^ M) on the field- 
s t imu 1 a t i o n *■ i nduc e d overflow of in atria. The first 3
open histograms show control responses prior to drug 
addition. The first diagonal striped histogram shows the 
potentiating effect of prazosin on this response. The 
next open histogram is a control response and the 
potentiating effect of prazosin is abolished. The second 
diagonal striped histogram again shows the potentiating
O
effect of prazosin on the overflow of H. Each column 
represents the mean (± S.E. mean) of 4 observations.
** 0.01> P > 0 .001, *** P<0.001 for comparison with control
prior to drug addition.
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FIGURE 37. Effect of prazosin (10 M) on the field
stimulation-induced overflow of in the atria. The
first 3 open histograms show control responses prior to
drug addition. The first diagonal striped histogram shows
the lack of effect of prazosin on this response. The next
open histogram is a control response. The second diagonal
striped histogram again shows the lack of effect of
prazosin on the stimulation-evoked overflow of ^ C .  Each
column represents the mean (—  S.E. mean) of 4
ob s e r vations.
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PART V
FURTHER INVESTIGATION OF THE EFFECTS OF DRUGS OH THE STIMULATION- 
EVOKED RELEASE OF %  FROM ATRIA PREVIOUSLY INCUBATED IN [3H]-NA
Phentolamine (10 M) potentiated the stimulation-evoked overflow of 
3H. Acetylcholine (IO-7 M - 10_3M) inhibited the overflow of 3H in the 
presence of phentolamine (Fig. 38). The presence of phentolamine did 
not affect the ability of acetylcholine to inhibit H overflow at 
10"7 M or 10"6 M. At 10*"'* M acetylcholine was more effective at 
inhibiting 3H overflow in the absence than in the presence of 
phentolamine (Fig. 39).
Clonidine (10“® M - 10“5 M) was more effective at inhibiting 3H 
overflow in the absence than in the presence of atropine (10 6 M) 
(Fig. 40).
The combined inhibitory effects of clonidine (10 7 M) and 
acetylcholine (10“7 M) on 3H overflow were partially additive 
(Fig. 41).
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FIGURE 38. Effect of phentolamine and ACh in the presence
of phentolamine on the stimulation-evoked release of
in atria. The open histograms show control responses
prior to drug addition. The vertical striped histogram
shows the potentiating effect of phentolamine (10*"^ M) on
this response. The diagonal striped histogram shows the
—  8
effect of ACh (10 M) in the presence of phentolamine. 
The succeeding 3 shaded histograms show the inhibitory 
effect of ACh added in increasing concentrations 
(10-7 M - 10“ 5 M) in the presence of phentolamine. Each 
column represents the mean (—  S . E .  mean) of 6 
observations. ** 0.01>P>0.001 for comparison with 
phentolamine prior to ACh addition. *** PC0.001 for 
comparison with control prior to phentolamine addition.
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FIGURE 39. Dose %-response curves showing the inhibitory 
effects of ACh in the absence (0------ 0) and presence
—  fs
(0----- 0) of phentolamine (10 M) on the stimulation-
o
evoked overflow of H m  atria. Each point is the mean 
(- S.E. mean) of i 4 observations.
* 0.0 5 > P > 0 .01.
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FIGURE 40. Dose %-response curves showing the inhibitory
_ O _ C
effects of clonidine (10 M - 10 M) in the absence
(0----0) and in the presence of (•----- • ) of atropine
(10“ 6 M) on the stimulation-evoked overflow of in the 
atria. Each point is the mean (i S.E. mean) of f 4 
observations. * 0.05>P>0.01, ** 0 . 0 1 > P > 0 .001.
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FIGURE 41. Inhibitory effects of clonidine and ACh alone
and combined on the stimulation-evoked overflow of H
from atria. The stippled histogram shows the inhibitory
—  7
effect of clonidine (10 M) on H overflow. The diagonal 
striped histogram shows the inhibitory effect of ACh 
(10"7 M) on overflow. The final diagonal striped 
stippled histogram shows the additive effect of combining 
clonidine (10 7 M) and ACh (10 7 M) on overflow. Each 
column represents the mean (~ S.E. mean) of 4 
observations. *** P<0.001 for comparison with ACh or 
clonidine effect.
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Isoprenaline (10  ^ M - 10  ^ M) potentiated the stimulation-evoked
overflow of from atria previously incubated in [%]-NA (Fig. 42).
Isobutylmethylxanthine (IBMX) (10  ^ M) potentiated the stimulation- 
evoked release of from atria previously incubated in [^H]-NA
(Fig. 43).
A single dose (10 ^ M) of 8-Bromo-cAMP potentiated the stimulation- 
evoked release of from atria previously incubated in [^H]-NA
(Fig. 44).
A single dose (10 ^ M) of 8-Bromo-cAMP, in the presence of atropine 
(10 "* M), retained its ability to potentiate the stimulation-evoked
O O
release of H from atria previously incubated in [ H]-NA (Fig 45). 
Dimethylsulphoxide (DMS0) produced an increase in the stimulation-
q _ c
evoked overflow of H. Forskolin (10 M), dissolved in DMSO, produced
3
no further enhancement of H overflow above that produced by DMSO 
alone (Fig. 46). Conversely, DMSO produced no enhancement of the 
positive inotropic component of the post-stimulus response in 
spontaneously beating paired atria, while forskolin (IO-'* M), 
dissolved in DMSO, did potentiate this response (Table 3).
Animal pretreatment with pertussis toxin resulted in the loss of
_o q
ability of clonidine (10 M) to inhibit the overflow of H from
3
atria. The ability of clonidine to inhibit H overflow at higher 
concentrations (10-  ^ M - 10-"* M) was not affected by pertussis toxin 
pretreatment (Fig. 47). Pretreatment with pertussis toxin resulted in 
the abolition of the negative inotropic component of the post-stimulus 
response in spontaneously beating paired atria (Table 4).
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FIGURE 42. Effect of isoprenaline on field stimulation-
3evoked overflow of H m  atria. The open histograms show 
successive control responses prior to drug addition. The 
succeeding 4 diagonal striped histograms show the 
potentiating effect of isoprenaline added in increasing 
concentrations (10  ^ M - 10  ^ M) in the same experiments. 
Each column represents the mean (— S.E. mean) of 4 
observations.
* 0.05>P>0.01 for comparison with control prior to drug 
addition.
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FIGURE A3. Effect of IBMX on field stimulation-induced 
3overflow of H in atria. The open histograms show 
successive control responses prior to drug addition. The 
succeeding A diagonal striped histograms show the 
potentiating effect of IBMX (10  ^ M) present throughout 
this latter part of the experiment. Each column 
represents the mean (—  S.E. mean) of 6 observations.
* 0.05>P>0.01 for comparison with control prior to drug 
a d d i t i o n .
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FIGURE 44. Effect of a single dose of 8-Bromo-cAMP on 
field stimulation-evoked overflow of H m  atria. The 
first 2 open histograms show control responses prior to 
drug addition. The diagonal striped histogram shows the 
potentiating effect of 8-Bromo-cAMP (10 ^ M) on
O
stimulation-evoked H overflow. The final open histogram 
is a control response and the potentiating effect of 
8 Bromo cAMP is abolished. Each column represents the 
mean (—  S.E. mean) of 6 observations.
* 0.05>P>0.01 for comparison with control prior to drug
ad d i t i o n .
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FIGURE 45. Effect of a single dose of 8-Bromo— c A M P , in 
the presence of atropine (10""^ M) , on field stimulation- 
evoked overflow of H in atria. The first 2 open 
histograms show control responses carried out in the 
presence of atropine. The diagonal striped histogram 
shows the potentiating effect of 8-Bromo— cAMP (10- ^ M ) ,
O
in the presence of atropine, on stimulation-evoked JH 
overflow. The final open histogram is a control response 
carried out in the presence of atropine and the 
potentiating effect of 8-Bromo-cAMP is abolished. Each 
column represents the mean (—  S.E. mean) of jc 6 
observations.
*** PC0.001 for comparison with atropine control prior to 
8-Bromo-cAMP addition.
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FIGURE 46. Effect of DMSO and forskolin dissolved in DMSO 
on field stimulation-evoked H overflow in atria. The 5 
open histograms show successive control stimulations 
prior to drug addition. The shaded histogram shows the 
potentiating effect of the vehicle DMSO (1% v:v) on this 
response. The diagonal striped histogram shows the lack 
of additive effect of forskolin (10  ^ M) in comparison 
with DMSO alone. Each column represents the mean (* S.E. 
mean) of £ 4 observations.
*** p<0.001 for comparison with control prior to drug 
a d d ition.
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FIGURE 47. Dose %-response curves comparing the
o
inhibitory effect of clonidine on H overflow in atria 
from control (0— ■ ■0 ) and pertussis toxin pretreated 
(t •) rats. Pertussis toxin p'retreatment has
O
abolished the ability of clonidine to inhibit H
— 8overflow at a concentration of clonidine of 10 M. At 
higher concentrations of clonidine (10-  ^ M - 10”  ^ M) 
there is little or no difference in the ability of
O
clonidine to inhibit H overflow m  atria from control 
or pertussis toxin treated rats. Each column represents 
the mean (—  S.E. mean) of | 5 observations.
** 0.01>P>0.001.
Table 3. Effect of DMSO and forskolin dissolved in DMSO on the 
positive inotropic component of the post-stimulus 
response in spontaneously beating paired atria.
Treatment
Control stimulation 
(2Hz x 30s)
DMSO (1% v:v)
Forskolin (10“ 5 M)/DMS0 (1% V:V)
Mean Percentage (i S.E. Mean) 
Increase of Positive IPSR.
41.3 ±  5.2 (n = 6)
39.8 ±  3.6 (n = 6)
69.7 -  5.9 (n = 6 ) ***
*** p<0.001 for comparison between stimulation in the presence of 
forskolin dissolved in DMSO and DMSO alone.
Table 4. Effect of pertussis toxin pretreatment on the negative
inotropic component of the post-stimulus response of the 
spontaneously beating paired atria.
Pre-treatment Mean Percentage (—  S.E. Mean)
Decrease of Negative IPSR.
C o n t r o 1. Stimulation 35.7 4.1 (n=6)
(2Hz x 30s)
Pertussis toxin. 0.0 —  0.0 (n=5) ***
*** p < 0 .001 for comparison between response from control and 
pretreated atria.
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Sodium nitroprusside (10“8 M - 10“5 M), (Fig. 48) and
(10 ^ M - 10 3 M), (Fig. 49) produced a dose-dependent increase in the 
stimulation—evoked overflow of radioactivity from atria incubated in 
[3H]-NA.
Administration of 8-Bromo-cGMP (10“6 M - 10~* M) also resulted in a 
potentiation of the stimulation-evoked release of 3H (Fig. 50).
Sodium nitroprusside (10 3 M) was able to reverse the inhibitory 
effect of clonidine (10 3M) on the overflow of 3H. In contrast, 
sodium nitroprusside (10-3 M) was unable to reverse the inhibitory 
effect of acetylcholine (10~3 M) on 3H overflow (Fig. 51).
—7 • 3In the presence of atropine (10 M), which potentiated H overflow,
sodium nitroprusside (10 ^ M) was able further to enhance the overflow
of 3H (Fig. 52). In contrast, in the presence of a higher
 r > 9
concentration of atropine (10 M), which also potentiated H 
overflow, a higher dose of sodium nitroprusside (10“3 M) was unable to 
further enhance the overflow of H (Fig. 53).
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FIGURE 48. Effect of sodium nitroprusside (SNP) on
O
field stimulation-evoked overflow of JH in atria at a
frequency of 2Hz for a period of 30 sec. The open
histograms show successive control responses prior to
drug addition. The succeeding 4 shaded histograms show
the potentiating effect of SNP added in increasing
— R - S
concentrations (10 M - 10 M) in the same 
experiment. Each column represents the mean (“  S.E. 
mean) of £ 4 observations.
** 0.05>P>0.01 for comparison with control prior to 
drug addition.
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FIGURE 49. Effect of SNP on field stimulation-induced
o
overflow of H m  atria at a frequency of 5Hz for a 
period of 12 sec. The open histograms show successive 
control responses prior to drug addition. The 
succeeding 3 diagonal striped histograms show the 
potentiating effect of SNP added in increasing 
concentrations (10  ^ M - 10 M) in the same 
experiment. Each column represents the mean (-i S.E. 
mean) of { 4 observations.
* 0.05>P>0.01, ** 0.01>P>0.001 for comparisons with 
control prior to drug addition.
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FIGURE 50. Effect of 8-Bromo-cGMP on field stimulation-
3
evoked overflow of H m  atria. The open histograms 
show successive control responses prior to drug 
addition*The succeeding 3 diagonal striped histograms 
show the potentiating effect of 8— Bromo-cGMP added in
— fi — A
increasing concentrations (10 M - 10 M) in the same 
experiment. Each column represents the mean (—  S.E. 
mean) of 4 observations.
* 0.05>P>0.01, ** 0.01>P>0.001 for comparison with 
control prior to drug addition.
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FIGURE 51. Effect of SNP on the inhibitory effect of 
clonidine and ACh on field stimulation-evoked overflow of 
in atria. In the top panel the open histogram is a control 
response. The shaded histogram shows the potentiating effect 
of SNP (10‘ 5 M) on this response. The vertical striped 
histogram shows the inhibitory effect of clonidine (10"""* M) 
on this response. The shaded vertical striped histogram 
shows the ability of SNP to reverse the inhibitory effect of 
clonidine. In the lower panel the open histogram is a 
control response. The vertical striped histogram shows the 
inhibitory effect of ACh (10- "* M) on this response. The 
shaded vertical striped histogram shows the inability of SNP 
(10“ 5 M) to reverse this effect of ACh. Each column 
represents the mean (—  S.E. mean) of 4 observations.
** 0. 0 1 > P > 0 .001, *** P<0.001.
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FIGURE 52. Effect of SNP in the presence of atropine on
O
the field stimulation-evoked release of H in atria.
The open histograms show successive control responses 
prior to drug addition. The succeeding 2 diagonal 
striped histograms show the potentiating effect of 
atropine (10  ^ M) on this response. The final 2 shaded 
histograms show the significant additional potentiating 
effect of SNP (10  ^ M) on this response. Each column 
represents the mean (—  S.E. mean) of A observations.
* 0.05>P>0.01 for comparison with atropine and 
atropine/SNP response. ** 0.01>P>0.001 for comparison 
with control prior to atropine addition.
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FIGURE 53. Effect of SNP in the presence of atropine on
O
the field stimulation-evoked release of H in atria.
The open histograms show successive control responses 
prior to drug addition. The shaded histogram shows the 
potentiating effect of atropine (10” "* M) on this 
response. The diagonal striped histogram shows the 
inability of SNP (10” '* M) to further potentiate the 
response in the presence of atropine. Each column 
represents the mean (—  S.E. mean) of 4 observations.
** 0.01>P>0.001 for comparison with control prior to 
atropine addition.
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PART VI
FURTHER INVESTIGATION OF THE EFFECTS OF DRUGS ON THE STIMULATION- 
EVOKED RELEASE OF 14C FROM ATRIA PREVIOUSLY INCUBATED IN [l4C]-CHOLINE
Sodium nitroprusside (10”** M, 10“'* M) inhibited the stimulation-evoked 
release of from atria previously incubated in [^C]-choline
(Fig. 54).
A combination of prazosin (10 "* M) and yohimbine (10 ■* M) potentiated 
the stimulation-evoked overflow of ^ C. In the presence of these
—  ft
alpha-adrenoceptor antagonists sodium nitroprusside (10 M) retained 
its ability to inhibit the stimulation-evoked overflow of 
(Fig. 55).
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FIGURE 54. Effect of SNP on the field stimulation- 
evoked release of in atria. The 3 open histograms
show successive control responses prior to drug 
addition. The first shaded histogram shows the 
inhibitory effect of SNP (10” ** M) on this response. The 
following open histogram is a control response and the 
inhibitory effect of SNP is abolished. The final shaded 
histogram again shows the inhibitory effect of SNP 
(10“ 5 M) on this response. Each column represents the 
mean (—  S.E. mean) of 6 observations.
* 0.05>P>0.01, ** 0.01>P>0.001 for comparison with 
control prior to drug addition.
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FIGURE 55. Effect of SNP in the presence of prazosin 
(10"5 M) and yohimbine d o " 6 M) on the field 
stimulation-evoked release of in atria. The 2 open
histograms show successive control responses prior to 
drug addition. The first diagonal striped histogram 
shows the significant potentiating effect of prazosin 
and yohimbine on this response. The first stippled 
histogram shows the significant inhibitory effect of 
SNP (10"6 M) in the presence of prazosin and 
y o h imbine.The second diagonal striped histogram again 
shows the potentiating effect of prazosin and 
yohimbine. The second stippled histogram again shows 
the significant inhibitory effect of SNP (10-6 M) in 
the presence of prazosin and yohimbine. Each column 
represents the mean (—  S.E. mean) of 4 observations.
* 0.05> P > 0 .01, **0.0 1 > P > 0 .001 .
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PART VII
EFFECTS OF SODIDM NITROPRUSSIDE OH THE CHRONOTROPIC RESPONSES OF THE 
HEART TO SERVE STIMULATION IH ANAESTHETISED AND PITHED RATS AND OH THE 
POSITIVE INOTROPIC RESPONSE OF FIELD STIMULATED SPONTANEOUSLY BEATING 
PAIRED ATRIA
Stimulation (10Hz x 5s) of the vagus nerve in anaesthetised rats 
resulted in a decrease in the heart rate. Sodium nitroprusside 
(60 jig Kg-*) did not affect this response (Fig. 56). The response to 
vagal stimulation, with these parameters, was potentiated by 
administration of prazosin (100 jig Kg *) and yohimbine (100 jig Kg *). 
Under these circumstances sodium nitroprussude inhibited the vagally- 
induced bradycardia (Figs. 57, 58).
In the anaesthetised rat intravenous administration of acetylcholine 
(0.6 jig Kg-*) produced a negative chronotropic effect on heart rate. 
Sodium nitroprusside (60 i^g Kg-1) did not affect this response 
(Fig. 59). Prazosin (100 ;ig Kg-1) and yohimbine (100 jig Kg-*) did not 
affect the response to exogenous acetylcholine, nor did a combination 
of prazosin, yohimbine and sodium nitroprusside affect the response 
to exogenous acetylcholine (Fig. 60).
Stimulation (5Hz X 10s) of the vagus nerve in pithed rats resulted in 
a decrease in heart rate. Sodium nitroprusside (60 jig Kg-1) produced 
an attenuation of this vagally-induced bradycardia (Figs. 61, 62).
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FIGURE 56. Effect of SNP on the response of the heart 
rate to vagus nerve stimulation (10Hz x 5 sec) in the 
anaesthetised rat. The open histogram shows that vagal 
stimulation results in a decrease in heart rate. The 
diagonal striped histogram shows that SNP does not 
affect this response. Each column represents the mean 
(—  S.E. mean) of 7 observations.
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FIGURE 57. Recording of the effects of vagal 
stimulation (10Hz x 5 sec) on heart rate in the 
anaesthetised rat and the effects of prazosin and 
yohimbine and SNP on this response. Stimulation of the 
vagus resulted in a decrease in heart rate. 
Administration of prazosin and yohimbine potentiated 
this response. SNP inhibited the response in the 
presence of prazosin and yohimbine.
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FIGURE 58. Potentiating effect of prazosin and 
yohimbine and reversal by SNP on the response of the 
heart rate to vagal stimulation (10Hz x 5s) in the 
anaesthetised rat. The open histogram shows that 
stimulation of the vagus nerve results in a decrease in 
heart rate. The diagonal striped histogram shows the 
significant potentiating effect of prazosin and 
yohimbine on this response. The vertical striped 
histogram demonstrates the ability of SNP to 
significantly inhibit the response to vagal stimulation 
in the presence of prazosin and yohimbine. Each column 
represents the mean (-i S.E. mean) of 6 observations.
** 0.01>P>0 . 001 .
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FIGURE 59. Effect of SNP on the response of the heart 
rate to exogenous ACh administration in the 
anaesthetised rat. The open histogram shows the 
inhibitory effect of ACh on the heart rate. The 
diagonal striped histogram shows that SNP does not 
affect the response to ACh administration. Each column
represents the mean (— S.E. mean) of 6 observations.
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FIGURE 60. Effect of prazosin and yohimbine, and 
prazosin, yohimbine and SNP on the response of the 
heart rate to exogenous ACh administration in the 
anaesthetised rat. The open histogram shows that ACh 
administration results in a decrease in heart rate. The 
diagonal striped histogram shows that prazosin and 
yohimbine do not affect this response. The stippled 
histogram shows that prazosin, yohimbine and SNP do not 
affect the response to exogenous ACh administration. 
Each column represents the mean (—  S.E. mean) of 6 
observat i o n s .
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FIGURE 61. Recording of the effects of vagal 
stimulation (5Hz x 10s) on heart rate in the pithed rat 
and the effect of SNP on this response. Two control 
stimulations result in a decrease in heart rate. 
Administration of SNP results in an attenuation of the 
response of the heart rate to vagal stimulation.
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FIGURE 62. Effect of SNP on the response of the heart 
rate to vagal stimulation (5Hz x 10s) in the pithed 
rat. The open histogram shows that vagal stimulation 
results in a decrease in heart rate. The diagonal 
striped histogram shows that SNP inhibited this 
response. Each column represents the mean (—  S.E. mean) 
of 4 observations.
* 0.05>P>0.01 for comparison with control prior to drug 
add i t i o n .
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Stimulation (10Hz x 10s) of the vagus nerve in pithed rats frequently 
resulted in a biphasic chronotropic response (Fig. 63). This response 
consisted of a transient negative chronotropic component and a 
positive chronotropic component. The former, negative component could 
be abolished by atropine (50 pg Kg-*) administration (Table 5a), while 
the latter, positive component could be abolished by propranolol 
(50 pg Kg *) administration (Table 5b).
Sodium nitroprusside (60 pg Kg-*) administration resulted in a small 
attenuation of the negative component of the biphasic response 
(Fig. 63). Sodium nitroprusside potentiated and prolonged the positive 
chronotropic component of the response (Figs. 63, 64, 65).
Intravenous administration of NA (0.1 pg Kg-*) in pithed rats resulted 
in an increase in the rate of beating of the heart. Sodium 
nitroprusside (60 pg Kg-*) did not affect this response (Fig. 66).
Stimulation (2Hz x 30s) of the cardio-accelerator nerves in the spinal 
column resulted in an increase in the rate of beating of the heart. 
This response was not affected by administration of sodium 
nitroprusside (60 pg Kg *) (Fig 67).
Field stimulation of isolated spontaneously beating paired atria 
resulted in an increase in the force of contraction of the beating 
atria. This response was potentiated by sodium nitroprusside (10-  ^ M) 
and by atropine (10-  ^ M). A combination of sodium nitroprusside and 
atropine did not result in a further enhancement in the response of 
the atria above that produced by either drug alone(Fig 68).
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FIGURE 63. Recording of the effects of vagal 
stimulation (10Hz x 10s) on heart rate in the pithed 
rat and the effects of SNP on this response.
Stimulation of the vagus results in a biphasic effect 
on the heart rate. This consists of a decrease in heart 
rate which is transient as the response rapidly 
develops into an increase in heart rate. Administration 
of SNP results in a small attenuation of the negative 
chronotropic response and a marked potentiation and 
prolonging of the positive chronotropic response.
Table 5a. Effect of atropine on the negative component of the 
chronotropic response following vagal stimulation 
in the pithed rat.
Treatment
Control. Stimulation 
(10Hz x 10s)
Atropine ( 50jig Kg” *)
*** p<0.001 for comparison 
presence of atropine.
Mean Decrease (—  S.E. Mean) 
In Heart Rate (BPM).
15.4 - 2.1 (n = 8 )
0.0 -  0.0 (n = 8 ) *** 
response in the absence and
Table 5b. Effect of propranolol on the positive component of the 
chronotropic response following vagal stimulation 
in the pithed rat.
Treatment Mean Increase (- S.E. Mean)
In Heart Rate (BPM).
Control. Stimulation 40.3 — 7.4 (n=8)
(10Hz x 1 0 s )
Propranolol (50;ig Kg ” 1 ) 3.1 -  1.5 (n=8) ***
*** PC0.001 for comparison between response in the absence and 
presence of propranolol.
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FIGURE 64. Effect of SNP administration on the positive 
chronotropic response of the heart rate produced by 
vagal stimulation (10Hz x 10s) in the pithed rat. The 
open histogram shows that stimulation of the vagus at 
these parameters can result in an increase in heart 
rate. The diagonal striped histogram shows that 
administration of SNP can potentiate this response to 
vagal stimulation. Each column represents the mean 
(—  S.E. mean) of 8 observations.
** 0 . 0 1 > P > 0 .001.
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FIGURE 65. Effect of SNP administration on the duration 
of the positive chronotropic response of heart rate 
produced by vagal stimulation (10Hz x 10s) in the 
pithed rat. The open histogram shows the duration of 
the positive chronotropic component of the response.
The diagonal striped histogram demonstrates the ability 
of SNP to prolong this response. Each column represents 
the mean ( —  S.E. mean) of 8 observations.
*** P<0.001.
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FIGURE 66. Effect of SNP on the response of the heart 
rate to exogenous NA administration in the pithed rat. 
The open histogram shows the potentiating effect of NA 
on the heart rate. The diagonal striped histogram shows 
that SNP does not affect the response to exogenous NA 
administration. Each column represents the mean 
(- S.E. mean) of 4 observations.
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FIGURE 67. Effect of SNP on the response of the heart 
rate to cardio-accelarator nerve stimulation (2Hz x 30s) 
in the pithed rat. The open histogram shows that cardio- 
accelarator nerve stimulation results in an increase in 
heart rate. The diagonal striped histogram shows that 
SNP did not affect this response. Each column represents 
the mean (—  S.E. mean) of 4 observations.
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FIGURE 68. Effect of SNP in the absence and presence of 
atropine on the positive inotropic component of the 
post-stimulus response of the spontaneously beating 
atria of the rat. The open histogram shows that field 
stimulation (2Hz x 30s) results in an increase in the 
force of contraction of the beating atria. The stippled 
histogram shows that SNP (10 M) can potentiate this 
response. The diagonal striped histogram shows that 
atropine (10 M) can also potentiate this response. The 
stippled diagonal striped histogram shows that a 
comb inat ion of SNP and atropine does not produce a 
further enhancement of the response. Each column 
represents the mean (i S.E. mean) of 6 observations.
** 0.01>P>0.001 for comparison with control prior to 
drug a d d i t i o n .
63
PART VIII
EFFECTS OF THYROXINE PRETREATMENT ON PRE- AMP POST-SYNAPTIC RECEPTOR 
SENSITIVITY IN ISOLATED ATRIA
Thyroxine (T^) pretreatment increased serum free levels (Fig. 69). 
This change was accompanied by alterations in the sensitivity of the 
atria to agonists acting at pre- and post-synaptic sites.
T^ pretreatment potentiated the inherent rate of beating of the
isolated atria. The pretreatment enhanced the ability of isoprenaline
(lO-^® M - 10“5 M) to increase the rate of beating of isolated
spontaneously beating paired atria but had little effect on the
maximum percentage increase in rate produced by the drug
(Figs. 70, 71, 7 2 ). Control atrial rate: 251 beats m i n " 1 .
T^ pretreated atrial rate: 375 beats m i n " ^ .
T^ pretreatment did not affect the sensitivity of the atria to
—9 —5carbachol. Carbachol (10 M - 10 M) inhibited the rate of beating 
of the atria in a dose-dependent manner and the pretreatment had
little effect on the maximum percentage inhibition produced by this
drug (Figs. 73, 74, 75)
In paced left atria, phenylephrine (10-  ^ M - 10"”^  M) produced a dose- 
dependent increase in the force of contraction of the atria. This 
response was blocked by prazosin (10 ^ M) (Fig. 76). T^ pretreatment 
reduced the percentage increase inotropic response produced by 
phenylephrine (Fig. 77).
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FIGURE 69. Effect of pretreatment in rats on 
unbound in plasma, measured in pmol free T^/] 
column represents the mean (—  S.E. mean) of 9 
observations. *** P<0.001.
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FIGURE 70. Dose-response curves showing the positive 
chronotropic effect of isoprenaline in spontaneously 
beating paired atria from control (0 0) and pre­
treated (•----- • ) rats. The vertical axis-expresses the
effects of isoprenaline in absolute B.P.M. Each point is 
the mean (—  S.E. mean) of £ 8 observations.
*** PC0.001.
A B.P.M. •***
200 -
1 5 0 -
100-
5 0 -
10 9 8 6 57
-log-|Q M isoprenaline
FIGURE 71. Dose-response curves showing the positive 
chronotropic effect of isoprenaline in spontaneously- 
beating paired atria from control (0----- 0) and pre­
treated (i •) rats. The vertical axis expresses the
effects of isoprenaline as the change in rate ( A b .P.M) 
above the resting level of beating. Each point is the 
mean (—  S.E. mean) of jc 8 observations.
** 0.01>P>0.001, *** P < 0 .00 1 .
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F I G U R E  72. Dose %-response curves showing the p o s itive 
c h r o n o t r o p i c  effect of isoprenaline in s p o n t a n e o u s l y  
b e a t i n g  paired atria from control (0—  0) and p r e ­
t r eated (•----- • ) rats. Each point is the m e a n  (—  S.E.
mean) of fc8 observations.
*** P<0.001.
B.P.M.
300-
200 -
100
9
-log-jo carbachol
FIGURE 73. Dose-response curves showing the negative 
chronotropic effect of carbachol in spontaneously
beating atria from control (0----- 0) and pre-treated
(f 9) rats. The vertical axis expresses the effects
of carbachol in absolute B.P.M. Each point is the mean 
(1 S.E. mean) of 10 observations.
*** P<0.001.
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FIGURE 74. Dose-response curves showing the negative 
chronotropic effect of carbachol in spontaneously 
beating paired atria from control (0------ 0) and pre­
treated (•----- • ) rats. The vertical axis expresses the
effects of carbachol as the change in rate (/ \ B .P .M .) 
below the resting level of beating. Each point is the 
mean (— S.E. mean) of 10 observations.
*** P<0.001,.
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FIGURE 75. Dose %-response curves showing the negative 
chronotropic effect of carbachol in spontaneously 
beating paired atria from control (0— — — 0) and pre­
treated (f • ) rats. Each point is the mean (—  S.E.
mean) of 10 observations.
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FIGURE 76. Dose %-response curve showing the inotropic
effect of phenylephrine in the absence (0------ 0) and in
the presence (•----- •) of prazosin in the electrically
paced left atria of the rat. Each point is the mean 
(i S.E. mean) of 6 observations.
* 0.05> P > 0 .01, ** 0 . 0 1 > P > 0 .001.
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FIGURE 77. Dose %-response curves showing the inotropic 
effects of phenylephrine on the electrically paced left
atria from control (0----- 0) and pre-treated (• • )
rats. Each point is the mean (—  S.E. mean) of 6 
observations.
* 0.05>P>0.01, ** 0.01>P>0.001, *** P < 0 .001.
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pretreatment increased the positive inotropic component of the 
post-stimulus response in isolated spontaneously beating paired atria 
(Fig. 78). In addition, pretreatment reduced the negative inotropic 
component of the post-stimulus response in isolated spontaneously 
beating paired atria (Fig. 79).
pretreatment reduced the ability of clonidine (10-  ^ M - 10""'* M) to 
inhibit the positive inotropic component of the post-stimulus response 
in the presence of atropine (10-8 M) (Fig. 80).
— Q — K
pretreatment reduced the ability of clonidine (10 M - 10 M) to 
inhibit the stimulation-evoked overflow of H from atria previously 
incubated in [8H]-NA (Fig. 81).
pretreatment did not affect the ability of acetylcholine 
(10~8 M - lO-'* M) to inhibit the stimulation-evoked overflow of 8H 
from atria previously incubated in [ H]-NA (Fig. 82).
1 / Q
In atria previously incubated in [ C]-choline and [ H]-NA; 
pretreatment reduced the ability of clonidine (10""'* M) to inhibit the
O
stimulation-evoked overflow of H. pretreatment did not affect the
— tr o
ability of acetylcholine (10 M) to inhibit H overflow, or the 
ability of clonidine (lO-** M) or acetylcholine (lO”"* M) to inhibit the 
simultaneous evoked overflow of (Fig. 83).
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FIGURE 78. Effect of pre-treatment on the positive 
inotropic component of the post-stimulus response in 
spontaneously beating paired atria. Frequency response
curves were constructed on atria from control (0------ 0)
and from pre-treated (•------ •) rats. Each point
represents the mean (— S.E. mean) of fC 4 observations.
* 0.0 5 > P > 0 .001.
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FIGURE 79. Effect of pre-treatment on the negative 
inotropic component of the post-stimulus response in 
spontaneously beating paired atria. Frequency response
curves were constructed in atria from control (0------ 0)
and from pre-treated (•------ •) rats. Each column is
the mean (- S.E. mean) of {6 observations.
* 0.05>P>0.01, **0.01> P > 0 .001, *** P < 0 .001.
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FIGURE 80. Dose %-response curves showing the inhibitory
— fi
effects of clonidine (in the presence of atropine (10 M))
on the positive inotropic component of the post-stimulus 
response in atria from control (0 0) and from----- pre­
treated (•----- • ) rats. Atria were-stimulated at 5Hz for a
period of 4 seconds. Each point is the mean (~ S.E. mean) of 
5 observations. * 0.05>P>0.01.
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FIGURE 81. Dose %-response curves showing the effects of
3
clonidine on the stimulation-evoked overflow of H in
atria from control (0 0) and from pre-treated
(•----- •) rats. Each point is the mean (—  S.E. mean) of
{ 6 observations.
* 0.05>P>0.01, ***P<0.001.
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FIGURE 82. Dose %-response curves showing the effects of 
ACh on the stimulation-evoked overflow of H m  atria
from control (0----- 0) and from pre-treated (•------ •)
rats .
Each point is the mean (—  S.E. mean) of 4 observations.
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FIGURE 83. Effect of clonidine and ACh on the 
stimulation-evoked (5Hz x 105s) release of and in
atria from control and pre-treated rats. The first 2
histograms show the significant attenuation in the
« —  C  O
ability of clonidine (10 M) to inhibit H overflow in 
pre-treated atria. The second pair of histograms show 
the lack of effect of T^ pre-treatment on the ability of 
ACh (10-5 M) to inhibit ~*H overflow. The third pair of 
histograms show the lack of effect of T^ pre-treatment 
on the ability of clonidine (10-  ^ M) to inhibit 
overflow. Finally, the fourth pair of histograms show 
the lack of effect of T^ pre-treatment on the ability of 
ACh (10~'*-M) to inhibit overflow. Each column
represents the mean (—  S.E. mean) of { 3 observations.
* 0.05>P>0.01.
DISCUSSION
PRESYNAPTIC INTERACTIONS OF THE ADRENERGIC AND CHOLINERGIC NERVES
The heart receives an excitatory adrenergic innervation and an
inhibitory cholinergic innervation (Randall, 1977). Many of the
terminal fibres of the sympathetic and parasympathetic systems lie in 
close proximity to each other in the heart (Jacobowitz et al, 1967; 
Ehinger et al, 1970). This anatomical arrangement provides an
opportunity to study the complex interactions between the peripheral 
neurones of these two subdivisions of the autonomic nervous system. 
This study sought to confirm the existence of such interactions and to 
examine the nature of the presynaptic control exerted by these nerves.
The study, by examining the effect of nerve stimulation to the heart 
in situ and also by field stimulating spontaneously-beating isolated 
rat atria in vitro provided strong evidence for neural interactions. 
The pithed rat preparation was employed as this allowed independent 
and simultaneous stimulation of the cardio-accelerator nerves in the
spinal column and of the vagus nerve in the neck of the pithed animal.
Stimulation of the cardio-accelerator nerves via an electrode in the 
spinal column produced an increase in heart rate; an effect that was 
abolished by propranolol and TTX. Stimulation of the vagus nerve in 
the neck produced a decrease in heart rate; an effect that was 
abolished by atropine and TTX. If the two sets of nerves were 
stimulated simultaneously or if the vagus nerve was stimulated in the 
presence of a dose of exogenous NA, both of which caused an increase 
in heart rate, then the response to vagal stimulation was enhanced.
This enhancement of a response to vagal stimulation, with respect to 
heart rate, against a background of raised sympathetic activity has 
been termed "accentuated antagonism" (Levy, 1971; 1984).
Accentuated antagonism is a common phenomenon which is widely 
recognised and can be produced in a variety of species (Samman, 1935; 
Warner & Cox, 1962; Warner & RusselJ, 1969; Levy & Zieske, 1969). The 
study also found that the response to vagal stimulation was greater 
in anaesthetised animals, in which, there exists a basal sympathetic 
tone and consequently an increased basal heart rate, than in pithed 
animals which have no sympathetic tone and consequently a decreased 
basal heart rate.
It is generally accepted that the inhibitory influence of vagal 
stimulation or exogenous ACh predominates over adrenergically-induced 
cardio-stimulation. It has been demonstrated in this study that the 
effects of vagal stimulation are exaggerated against a raised 
sympathetic tone.
Further evidence of interaction between the sympathetic and 
parasympathetic nerves was again derived from stimulation of the vagus 
nerve in the pithed rat and the consequent effect on heart rate. At a 
frequency of 10Hz, stimulation of the vagus nerve produced a biphasic 
effect on heart rate. This response consisted of a decrease in heart 
rate followed by an increase in heart rate. The fall in heart rate 
could be abolished by administration of atropine, while the increase 
in heart rate could beinhibited by propranolol. This observation 
suggests that, at this frequency, stimulation of the vagus nerve 
results not only in excitation of inhibitory cholinergic fibres but 
also of stimulatory adrenergic fibres contained in the vagosympathetic
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trunk. Such observations have previously been encountered (Loewi, 
1921; Iano et al, 1973)'} however, different explanations have been 
offered to explain the secondary cardioaccelerator component of vagal 
stimulation. In the case of the observations of Loewi (1921), as with 
this study, the vagal excitation appeared to be due to unavoidable 
excitation of sympathetic nerves in the vagosympathetic trunk. 
However, unlike the current study, that of Iano et al (1973), produced 
a vagal excitation which was not propranolol-sensitive but was 
atropine-sensitive. This accelerator component of parasympathetic 
control of the heart was postulated to be due to an action of ACh on 
sino-atrial nodal cells.
The evidence of sympathetic-parasympathetic interactions in the heart 
in situ was supplemented with experiments carried out on the isolated, 
spontaneously-beating paired atria from the rat. Field stimulation of 
such atria produced a complex post-stimulus response. During the 
period of stimulation the atria were driven electrically if the 
frequency of stimulation was faster than inherent rate of beating. If 
the frequency of stimulation was lower than the inherent rate of 
beating then the inherent rate was interrupted by the field 
stimulation. Immediately following stimulation a transient negative 
inotropic response arose that lasted about 2-3 seconds, before 
developing into a positive chronotropic and inotropic response. This 
preparation has been employed previously (Idowu & Zar, 1977), as has 
the equivalent preparation in the guinea-pig (Vizi et al, 1973). In 
the study by Idowu & Zar, the positive chronotropic response of rat 
atria to field stimulation was studied. This response was found to be 
blocked by propranolol and inhibited by clonidine suggesting that the 
increase in atrial rate after electrical stimulation was due to the 
release of NA.
The present study examined the effects of field stimulation of the 
isolated atria in detail. The effects of field stimulation of the 
atria were complex since they appeared to be the resultant not only of 
the postsynaptic excitatory effects of NA and the postsynaptic 
inhibitory effects of ACh but also because they reflected, in part, 
the presynaptic interactions of NA and ACh, which together modulated 
transmitter release. It is clear that the post-stimulation 
chronotropic and inotropic responses were neurally-mediated since TTX 
blocked both responses but allowed pacing of the atria to continue 
during stimulation. The positive chronotropic effects reached a 
maximum response, in terms of percentage increase, that was 50% less 
than the maximum response produced for the concomitant positive 
inotropic response. Thus, field stimulation of atria produced a 
minimal effect on heart rate but a large effect on the force of 
contraction.
The positive chronotropic response could be blocked by propranolol and 
guanethidine. However, the positive chronotropic response was 
insensitive to addition of atropine. The insensitivity of the 
chronotropic response to atropine is surprising, particularly since 
atropine inhibited the negative inotropic response and powerfully 
potentiated the positive inotropic component. Since the chronotropic 
response was measured in the transitional period from negative to 
positive inotropy and since this was lost in the presence of atropine, 
it is possible that the effect of atropine on the chronotropic 
response was masked due to the loss of this transitional phase.
The negative inotropic response reached a maximum percentage 
inhibition of force of contraction of 7-8Hz and was abolished by 
atropine. This response was not significantly affected by addition of
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propranolol. These results suggest that the negative inotropic 
component of the post-stimulus response is due to the release of ACh. 
The post-stimulus positive inotropic response was sensitive to a 
variety of drugs. This response was abolished by reserpine 
pretreatment and inhibited by guanethidine and propranolol suggesting 
that field stimulation released NA from sympathetic nerves. The 
positive inotropic response was potentiated by atropine suggesting 
that neurally-released ACh normally acted to attenuate the response. 
Atropine potentiated this response by two possible mechanisms. First, 
atropine probably blocked postsynaptic muscarinic receptors, so that 
the ACh-mediated physiological antagonism of the effects of released 
NA was abolished. Secondly, atropine may have blocked presynaptic 
muscarinic receptors on sympathetic nerves, where ACh may have had a 
negative influence on NA release. The existence of presynaptic 
muscarinic receptors inhibiting NA release is well documented (for 
review see Muscholl, 1980).
Since the positive inotropic response was also potentiated by the 
alpha2 ~adrenoceptor antagonists yohimbine, and the less specific 
phenoxybenzamine, which also blocks neuronal and extraneuronal uptake 
of NA, apparently there was considerable endogenous negative feedback 
of NA release in the atria. In spite of the apparent ability to block 
presynaptic alpl^-adrenoceptors with antagonists as reflected in a 
increased mechanical response of the tissue following field 
stimulation, clonidine the alpt^-adrenoceptor agonist did not inhibit 
the positive inotropic post-stimulus response. This was a surprising 
result since clonidine might have been expected to inhibit the release 
of NA by acting on alpl^-adrenoceptors on the sympathetic nerves. 
The lack of effect of clonidine together with the potentiating effect 
of yohimbine perhaps suggests that in the atria, with no clonidine
present, there is already substantial alpha2 -adrenoceptor-mediated 
feedback restricting NA release so that the addition of clonidine has 
little or no superimposed effect.
This hypothesis cannot, however, be sustained since, in the presence 
of atropine which increased the response of the atria, clonidine 
inhibited the positive inotropic post-stimulus component. The fact 
that a ten-fold higher dose of clonidine was employed in the presence 
of atropine is of no relevance since the hypothesis argues that the 
presynaptic alph^-adrenoceptor is being maximally stimulated. It is 
possible, however, that the initial dose of clonidine is too small to 
initiate activation of presynaptic alpha2 -adrenoceptors and this 
required further investigation (see below). However, the presence of 
atropine should further increase the release of NA, by blocking 
presynaptic muscarinic receptors on the sympathetic nerve terminal 
thus leading to more NA acting on the presynaptic alpha2 -adrenoceptor 
and if anything diminishing a potential effect of clonidine as opposed 
to unmasking one.
A possible explanation of the anomalous effects of clonidine in the 
absence and presence of atropine is that clonidine does indeed act on 
presynaptic alph^-adrenoceptors however, these are situated not only 
on the adrenergic nerve terminal but also on the cholinergic nerve 
terminal. Such an arrangement is plausible because otherwise there 
would be an asymmetrical distribution of presynaptic control of 
transmitter release. There is considerable pharmacological evidence 
for the existence of presynaptic alpha-adrenoceptors on the 
parasympathetic nerves in the gut, that act to modulate the release of 
ACh (Knoll & Vizi, 1970; Wikberg, 1978 a,b; Manber & Gershon, 1979; 
Davey, 1980) and also in the trachea (Baker & Don, 1987).
If alpha-adrenoceptors do exist on the parasympathetic nerves in the 
atria and if they regulate ACh as they regulate NA release in the 
sympathetic nerves then clonidine would not affect the positive 
inotropic post-stimulus response because clonidine would inhibit the 
release of ACh and NA simultaneously, so that the postsynaptic 
consequences would be negated. More importantly, if clonidine acted 
on alpha-adrenoceptors on parasympathetic nerves, inhibition of ACh 
release would also remove the inhibitory effects of ACh on presynaptic 
cholinoceptors on sympathetic nerves so that more NA would be 
released. This would be balanced by the inhibitory effects of 
clonidine at the alpha2 ~adrenoceptor on the sympathetic nerves so that 
it is unlikely that the positive inotropic response would be affected 
and almost certainly would not be reduced. Thus, the inhibitory effect 
of clonidine on NA release is only seen when the inhibitory effect of 
clonidine on ACh release is masked by the presence of atropine. It is, 
therefore, suggested that there are presynaptic inhibitory alpha- 
adrenoceptors not only on the sympathetic nerve terminals but also on 
the cholinergic nerve terminals in the atria.
The above evidence for adrenergic-cholinergic interactions and the 
existence of a presynaptic inhibitory alpha-adrenoceptor situated on 
the parasympathetic nerve terminal is circumstantial in so far as it 
attempts to interpret the effects of drugs thought to act 
presynaptically (Drew, 1976; Starke, 1977) to inhibit the release of 
transmitter by monitoring postsynaptic events. Although the atria has 
previously been used to study transmitter release by assaying the 
postsynaptic effects of drugs which act prejunctionally to affect 
transmitter release ( Idowu & Zar, 1977; Lew & Angus, 1983; Loiacono & 
Story, 1986) a more direct method of examining presynaptic receptors
would be to measure the output of transmitter. This eliminates the 
involvement of post-synaptic events in the analysis of results.
Since NA is known to be a transmitter in atria, part of this study 
investigated the effects of a variety of drugs on the release of NA 
from atria pre-incubated with [ H]-NA. Field stimulation of such 
atria increased the amounts of radioactivity released into the bathing 
solution. TTX abolished, in a dose-dependent manner, [ H]-NA overflow 
indicating it was neurally-mediated. Separation of [ H]-NA from its 
metabolites confirmed that the overflow collected was principally NA.
The inactivation of neurally-released NA is carried out by neuronal 
uptake, which reduces the concentration of released transmitter in the 
synaptic cleft (Langer, 1977). This study has shown that a 
combination of tranylcypromine, desmethylimipramine and 17, Beta- 
oestradiol, which block, respectively, monoamine oxidase (MAO) and the 
neuronal and extraneuronal uptake of NA, produced a significant
O
increase in the overflow of [ H]-NA. It has been proposed (Langer, 
1977) that blockade of neuronal uptake enhances the amount of 
transmitter available to activate presynaptic alpha-adrenoceptors 
leading to enhanced feedback inhibition. It is perhaps surprising, 
therefore, that uptake blockers, such as those employed, enhanced 
transmitter overflow. However, in the atria, cocaine, a neuronal 
uptake agent has been seen to increase transmitter overflow (McCulloch 
et al, 1972, Story & McCulloch, 1974) suggesting that despite the 
increased concentration of NA in the synaptic cleft the alph^- 
adrenoceptor feedback mechanism is not being fully activated. Two 
results from this study support this. First, clonidine still inhibits 
[^H]-NA release in the presence of tranylcypromine, 
desmethylimipramine and 17, Beta-oestradiol and secondly, yohimbine
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O
still enhances [ H]-NA release in the presence of these drugs. Thus, 
it appears as if the uptake blockers do enhance the stimulation- 
induced overflow of transmitter, but this has little effect on the 
presynaptic alpha-adrenoceptor feedback mechanism governing NA 
release.
The situation is remarkably complex if there is indeed a presynaptic 
alpha-adrenoceptor situated on the cholinergic nerve terminals. Since 
the presynaptic mechanisms are so sophisticated the increased 
concentration of NA, caused by the uptake blockers, would presumably 
further inhibit ACh release. This would result in a removal of ACh 
restraint on NA release via the presynaptic muscarinic receptor on the 
adrenergic nerve resulting in an even greater increase in NA overflow.
O  # O
Clonidine inhibited [ H]-NA overflow and yohimbine potentiated [ H]-NA 
overflow thus confirming the presence of presynaptic alpha2 ~ 
adrenoceptors on the adrenergic nerve and also that endogenous 
inhibition of NA release was mediated via these receptors. ACh
O
inhibited [ H]-NA release but at a lower concentration potentiated
O
[ H]-NA release. The potentiating action of ACh is surprising. The 
concentrations of ACh used were less than one-hundredth of those 
required to have any appreciable effect on the uptake of NA (Allen, 
1973) or to have any stimulatory effect on nicotinic receptors 
(Muscholl, 1980). Furthermore, nicotinic cholinoceptors do not appear
O
to modulate the release of [ H]-NA from rat isolated atria evoked by 
sympathetic nerve stimulation (Fuder et al, 1982). An enhancing
effect of very low concentrations of ACh on sympathetic transmission 
has been demonstrated in the mesenteric artery. The response was 
inconsistent and small. A similar enhancement of sympathetic 
stimulation after low concentrations of ACh release was reported for
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the rabbit ear artery (Rand & Varma, 1970). This effect was confirmed 
by Allen et al (1975) whose studies involved measuring [ H]-NA 
overflow. The phenomenon was found to be highly sensitive to changes 
in extracellular calcium ion concentration (Hope et al, 1978). Some 
reservation would be justified in attaching general significance 
the phenomenon since the effect has been sought but not found in 
rabbit pulmonary artery (Rand et al, 1975; Endo et al, 1977) in rabbit 
heart (Muscholl, 1973) in guinea-pig atria (Story et al, 1975) and in 
several blood vessels from the dog (Vanhoutte, 1977).
O
Atropine enhanced the release of [ H]-NA confirming the existence of 
an endogenous ACh-mediated restraint on NA release. The ability of 
atropine and yohimbine to potentiate field stimulation-induced [ H]-NA 
overflow confirmed what was suggested by the effects of these drugs on 
the mechanical response of the field-stimulated atria. The inhibitory
O
effect of clonidine of [ H]-NA overflow also confirmed the observation 
that clonidine could inhibit the inotropic post-stimulus^although only 
in the presence of atropine.
In this atrial preparation there are presynaptic alpha2 ”adrenoceptors 
and muscarinic cholinoceptors on the sympathetic nerve terminals and 
through these receptors, endogenous, neurally-released NA and ACh act 
simultaneously to inhibit further NA release. It seems clear that the
O
ability of yohimbine to potentiate field-stimulation induced [ H]-NA 
overflow by blocking NA-mediated auto-inhibition via presynaptic 
alpha2 _adrenoceptors on the sympathetic nerves would be restrained by 
the simultaneous blocking of the hypothetical presynaptic alpha- 
adrenoceptors on the parasympathetic nerve mediating regulation of ACh 
release. The increased amount of ACh thus released by yohimbine 
would, through an action on presynaptic muscarinic cholinoceptors on
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the sympathetic nerves, inhibit NA release. The study has shown that 
yohimbine and atropine had additive and at some concentrations
O
synergistic effects on [JH]-NA overflow. This synergistic
potentiation of field-stimulation-induced transmitter release is 
compatible therefore, with the existence of alpha-adrenoceptors on the 
cholinergic nerves as well as on the noradrenergic nerves.
These results confirm the initial observations obtained from the 
mechanical responses produced by field stimulated atria. They provide 
further evidence suggesting the existence of an inhibitory presynaptic 
alpha-adrenoceptor on the cholinergic nerve terminal but they do not 
permit direct measurement of the release of ACh and examination of the 
effects of presynaptic agonists and antagonists on this parameter.
In the course of this study atria were incubated in [^C]-choline. It
has been rigorously shown that the immediate precursors of ACh are
acetyl-CoA and choline, which is taken up into the parasympathetic
• • • +
nerves by means of a high-affmity Na -dependent uptake mechanism 
(Wetzel & Brown, 1983; Loffelholz _et al, 1984). It has been shown 
that incubation in radiolabelled choline results in incorporation of 
such choline as to form radiolabelled ACh. This method ensures that 
radiolabelled ACh synthesis occurs in the cholinergic neurones since 
non-neuronal cardiac cells do not contain choline acetyltransferase, 
the enzyme responsible for the synthesis of ACh in cholinergic 
neurones (Roskoski et al, 1977). With the addition, after incubation, 
of hemicholinium-3, which prevents the reuptake of choline (Jope, 
1979) and eserine, which inhibits the breakdown of ACh, field 
stimulation results in an overflow of [*^C] which is principally ACh.
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In the present study the procedure used to radiolabel the cholinergic 
transmitter pools was essentially that of Fosbraey & Johnson (1980). 
No attempt was made to account for radioactivity in terms of 
acetylcholine and its metabolite choline. Presumably, were it not for 
the presence of the cholinesterase inhibitor, eserine, a large
proportion of transmitter ACh released from the atrial cholinergic
nerves would have been subject to enzymatic destruction. The
stimulation-evoked ACh overflow from hearts of chicks, cats, guinea- 
pigs and rabbits is markedly increased in the presence of eserine, a 
cholinesterase inhibitor (Dieterich et al, 1976; 1978).
O
In rat isolated atria previously incubated in [ H]-choline most of the
O
efflux of radioactivity released by stimulation is present as [ H] —
O
ACh, whereas [H]-choline accounts for most of the efflux during
resting periods (Wetzel & Brown, 1985). Similar results have been 
obtained with tissues other than the heart which have been incubated 
in [ H]-choline to study cholinergic transmitter processes (Wikberg, 
1977). The field stimulation-induced overflow in this study was 
assumed, therefore, to represent ACh release, presumably from both 
pre-and post-ganglionic parasympathetic terminals within the atria. 
The [^C]- radiolabel was chosen to allow simultaneous incubation with
O
[ H]-NA thus permitting both neurotransmitters to be collected and 
measured separately. This allowed the effects of drugs on the field 
stimulation-induced release of both radiolabels to be examined in the 
same experiments,
Preliminary experiments were carried out in which the Krebs solution 
bathing the atria did not include eserine and hemicholinium. Under 
these circumstances no increase in [^C] overflow was observed. Only 
in the presence of these drugs was an appreciable increase in [^C]
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overflow observed following stimulation. This effect has been observed
O
on [ H]-choline overflow studies in the guinea-pig ileum (Fosbraey & 
Johnson, 1980). Field stimulation of atria incubated in [^H]-NA and 
[^■^C]-choline results in an increase in overflow of both these 
radiolabels.
With the parameters used in this study a descending level of overflow 
resulted with each consecutive stimulation at 10 minute intervals. 
TTX inhibited the stimulation-induced overflow of [^C] suggesting
that this was a neurally-mediated response. This study has shown that
the alpha-adrenoceptor agonist, clonidine, can inhibit the field-
1 / Q
stimulation-induced release of [ C] and [ H] simultaneously. In 
addition, the muscarinic receptor agonist, ACh, can also inhibit the 
field-stimulated release of [^C] and [^H]. These results suggests 
that there exists on the cholinergic nerve terminal a presynaptic 
alpha-adrenoceptor and a muscarinic receptor that when activated by 
exogenous agonists inhibit the field-stimulated release of ACh. The
muscarinic receptor antagonist, atropine, potentiated the release of 
[*^C]. These observations suggest that field stimulation of atria 
releases ACh, which acts on a presynaptic muscarinic receptor on the 
cholinergic nerve terminal to inhibit its own release; a system 
analogous to that of NA-mediated feedback inhibition via presynaptic 
alpha-adrenoceptors on adrenergic nerve terminals.
As previously suggested, there does appear to exist on the cholinergic 
nerve terminal an alpha-adrenoceptor which when activated by clonidine 
inhibits the release of ACh. Clonidine simultaneously inhibits NA- 
release. The study examined the effect of yohimbine and prazosin on 
[**H]-NA and [^C] overflow. It was found that yohimbine potentiated
o 1 /
the stimulation-induced overflow of [ H]-NA and [ C] . Prazosin, an
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alpha^-adrenoceptor antagonist failed to potentiate [^C] overflow but
• O
did potentiate [ H]-NA overflow. The results suggest that field 
stimulation of atria results in the release of NA.
It appears this NA acts on a presynaptic alpha-adrenoceptor on the 
cholinergic nerve terminal to inhibit release of ACh. The NA-mediated 
restraint of ACh release can be prevented by yohimbine but not by 
prazosin. This result partially confirms the observations of Wetzel 
et al (1985) and McDonough et al (1986). In these studies [^H]-ACh 
release was promoted by potassium depolarisation. Under these 
circumstances exogenous ACh could inhibit the potassium-induced 
release of [ H]-ACh overflow, while atropine could potentiate the
potassium-induced release of [ H]-ACh. In addition, these studies,
have characterised an inhibitory adrenoceptor on the cholinergic nerve 
as being of the alpha-^-subtype. Contrary to the results in this
9
study, it was found that clonidine was unable to inhibit [ H]-ACh 
overflow. Also, in contrast, these studies showed that selective
9
alpha^-adrenoceptor antagonists more powerfully potentiated [ H]-ACh 
overflow than selective alpha2 ~adrenoceptor antagonists. Although, 
there remains doubt as to the nature of alpha-adrenoceptor situated on 
the cholinergic nerve terminal, there is little doubt as to its 
existence and its ability to inhibit the release of ACh.
The ability of the alpha^-adrenoceptor antagonist, prazosin, to
9
potentiate the overflow of [ H]-NA is consistent with evidence
obtained for alpha-j.-adrenoceptor-mediated inhibition of NA released 
obtained in the rat (Kobinger & Pichler, 1982; Docherty, 1984) and the 
dog (Uchida et al, 1984).
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This study and recent studies clearly demonstrate that there exists on 
the cholinergic nerve muscarinic cholinoceptors and alpha- 
adrenoceptors which when activated by respective agonists inhibit the 
release of ACh. Previous studies concerned with the regulation of 
cardiac parasympathetic neurotransmission have assessed ACh release 
indirectly by examining physiological responses to vagal stimulation 
(Vincenzi & West, 1965; Hadhzy et al, 1973; Glitsch & Pott, 1978 a,b). 
Two such studies measuring chronotropic responses to vagal stimulation 
suggested that the release of ACh in the mammalian heart is regulated 
presynaptically by cholinergic (Yonehara et al, 1979) and adrenergic 
agents (Chassaing et al, 1983). These conclusions are consistent with 
the reported effects of cholinergic and adrenergic agents on ACh 
release in non-cardiac tissues (Wikberg, 1978(b); Koketsu & Yamada, 
1982).
Thus, while this study has provided evidence for adrenergic modulation 
of ACh release, a functional and physiological response demonstrating 
such modulation would be desirable. Therefore, rats were anaesthetised 
or pithed and the effects of vagal stimulation on heart rate in situ 
was monitored. In anaesthetised rats, in which there exists a basal 
sympathetic tone (McGrattan et al, 1987), the alpha-adrenoceptor 
antagonists prazosin and yohimbine significantly potentiated vagally- 
induced bradycardia. The bradycardia produced by exogenous ACh was 
unaffected by these drugs. These results suggest that vagal 
stimulation in anaesthetised rats caused release of ACh and that the 
release of ACh is tonically inhibited by noradrenaline presumably by 
activation of presynaptic adrenoceptors on the cholinergic nerve 
terminals. In addition, the study showed that phenylephrine, the
alpha^-selective adrenoceptor agonist, could attenuate vagally-induced 
bradycardia and that this effect could be reversed by prazosin.
80
Similarly, clonidine could also attenuate vagally-induced bradycardia 
and this attenuation could be partially reversed by yohimbine. In the 
pithed rat, clonidine was again able to attenuate vagally-induced 
bradycardia and as before yohimbine was only partially able to reverse 
this effect.
These results provide further evidence for the existence of an alpha- 
adrenoceptor inhibiting the neural release of ACh. The ability of 
phenylephrine to inhibit vagally-induced bradycardia and the reversal 
of this effect by prazosin has been reported elsewhere (McGrattan et 
al, 1987) and is believed to be further evidence in support of the 
adrenergic receptor on the cholinergic nerve terminal to be of the 
alpha^-subtype. However, doubt must still remain as to the nature of 
this receptor, since in this in vivo study, clonidine was able to 
attenuate the vagally-induced bradycardia, an effect which could be 
reversed by yohimbine. The results of the present study provide 
evidence in support of the speculative hypothesis proposed by Rand e_t 
al (1975, 1980) which suggested that the transmitters ACh and NA may 
act not only by having opposite effects on the post-junctional 
effector cells but also on transmitter release from the nerves with 
the opposing action. Thus, this study would suggest there exists 
presynaptic autoinhibition of transmitter release and also presynaptic 
mutual cross inhibition of transmitter release in the heart (Fig 84).
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FIGURE 84. Schematic representation of the presynaptic 
interactions between the adrenergic and cholinergic nerves 
in the atria. Field stimulation of the atria results in the 
simultaneous release of both ACh and NA, which act on a 
post-synaptic muscarinic receptor and beta-adrenoceptor 
respectively. ACh also acts to auto-inhibit its own release 
by acting on an inhibitory pre-synaptic muscarinic receptor 
on the cholinergic nerve terminal. ACh also inhibits the 
release of NA by acting on an inhibitory muscarinic receptor 
on the adrenergic nerve terminal. NA auto-inhibits its own 
release by acting on an inhibitory presynaptic alpha 2 ~ 
adrenoceptor on the adrenergic nerve terminal. In addition, 
NA inhibits the release of ACh by acting on an inhibitory 
alpha-adrenoceptor situated on the cholinergic nerve 
terminal. Such a system would result in a sophisticated 
control of the release of the 2 transmitters.
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INVOLVEMENT OF CYCLIC NUCLEOTIDES IN MODULATING THE RELEASE OF ACh AND 
HA
The release of NA from sympathetic nerves can be modulated by 
endogenous and exogenous substances acting on receptors situated on 
the nerve terminals (Langer, 1977; Starke, 1977; Muscholl, 1980). 
These receptors include beta-adrenoceptors, alpha-adrenoceptors, 
muscarinic cholinoceptors, dopamine receptors, opiate receptors and 
purinergic receptors among others (Langer, 1981). The presynaptic 
receptors which have been investigated most frequently are the 
inhibitory alpha2 ”adrenoceptor, the inhibitory muscarinic 
cholinoceptor and the facilitatory beta-adrenoceptor. Activation of 
the beta-adrenoceptor results in an enhancement of NA release. The 
ultimate effects of activation of these receptors are well documented 
however, the intraneuronal mechanisms through which these effects are 
mediated are still unknown.
The present study examined the hypothesis postulated by Loiacono et al 
(1985), who suggested that presynaptic muscarinic cholinoceptors and 
alpha2 -adrenoceptors on the sympathetic nerve terminal may interact so 
that activation of one type of receptor interferes with the 
effectiveness of an agonist acting at the other. The evidence for such 
a reciprocal interaction was the observation that phentolamine blocked 
alpha2 ”adrenoceptors and consequently increased NA release but 
paradoxically also enhanced the ability of exogenous ACh to inhibit NA 
release. It was suggested that the reciprocal interaction was due to 
the fact that both these receptors are competing for a final common 
intracellular pathway which ultimately regulates the availability of 
calcium ions for stimulus-response coupling (Gothert, 1977).
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Such an interaction between presynaptic receptors competing for a 
common intracellular pathway have previously been proposed. Thus, it 
has been shown that activation of prejunctional beta-adrenoceptors in 
enhancing NA release is inversely related to the degree of activation 
of the prejunctional alpha-adrenoceptors (Majewski & Rand, 1981). In 
addition, it has been suggested that alpha2 -adrenoceptors and opiate 
receptors located on nerve terminals in the vas deferens may be linked 
to a common mechanism that inhibits transmitter release (McCulloch & 
Pollock, 1985).
The present study re-examined the possibility of such a reciprocal 
interaction between the presynaptic alpha-adrenoceptor and the 
cholinergic muscarinic receptor on the sympathetic nerve. Repetition 
of the original experiments, whereby, the effectiveness of ACh at 
inhibiting NA release was examined in the absence and presence of 
phentolamine did not suggest that ACh was more effective at inhibiting 
NA release when the alpl^-adrenoceptor was blocked. Rather, at low 
concentrations ACh was equally effective at inhibiting NA release in 
the absence or in the presence of phentolamine. At a higher dose of 
ACh, phentolamine actually inhibited the ability of ACh to attenuate 
NA release. The discrepancy between the studies is interesting. The 
parameters of stimulation and concentration of drugs used were 
identical although the interval between stimulation differed as was 
the duration of exposure of the atria to drugs. The author and 
Loiacono can find no other explanation other than those cited for the 
discrepancy (Loiacono, personal communication).
However, the present study provided further evidence which suggested 
that the muscarinic and alpha2 “adrenoceptor did not feed into the same 
intracellular pathway. If the original hypothesis were true then the
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ability of an alpha-adrenoceptor agonist to inhibit NA release should 
be enhanced in the absence of endogenous ACh-mediated restraint. 
Thus, since field stimulation of isolated atria releases both ACh and 
NA then atropine should prevent endogenous ACh inhibiting NA release 
in a manner analogous to that of phentolamine preventing NA from
inhibiting its own release. The present study compared the ability of 
clonidine to inhibit NA release in the absence and in the presence of 
atropine. Therefore, the converse experiment to that performed by 
Loiacono et al (1985) was carried out. Thus, when the muscarinic 
receptor was blocked, by atropine, to remove ACh-mediated restraint of 
NA release the alpt^-adrenoceptor agonist, clonidine, was less
O
effective at inhibiting H overflow. This result is contrary to that 
predicted by the hypothesis of Loiacono et al, (1985). A possible
explanation of the result is that clonidine is less effective in the 
-presence of atropine because the ACh-mediated restraint on NA release 
is removed so that there is enhanced activation of alpha2 ~
adrenoceptors and thus the scope for clonidine to act on the alpha2 “ 
adrenoceptors is reduced.
The previous study (Loiacono et al, 1985) found that in arterial
preparations both exogenous ACh and clonidine inhibited NA overflow. 
Combining ACh with clonidine did not alter the inhibitory effect of 
clonidine. The present study also found that, in the atria, exogenous 
ACh and clonidine inhibited NA overflow, however, it also showed that 
the inhibitory effect of clonidine was enhanced in the presence of 
ACh. Indeed, the ability of clonidine and ACh to inhibit NA release 
were additive.
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Finally, the ability of atropine and yohimbine to produce at some 
doses a synergistic potentiation of field stimulation-induced NA 
overflow may also indicate that the two inhibitory pathways, activated 
respectively by ACh and NA, affect different stages in the process of 
excitation-secretion coupling.
The present study disagrees with the observation of Loiacono et al 
(1985) that the presynaptic muscarinic cholinoceptor and the 
presynaptic alpha2-adrenoceptor interact in such a way that they feed 
into a common pathway inhibiting the release of NA.
The nature of the intracellular pathways governing transmitter release 
are unknown. It has been proposed that activation of presynaptic 
adrenoceptors affects the release of NA from sympathetic nerves by 
altering adenylate cyclase activity and cyclic AMP formation 
(Rasmussen, 1970; Wooten et al, 1973; Cubeddu et al, 1975; Stjarne, 
1979). It is possible that alterations in endogenous cAMP production 
may explain the modulatory effects of alpha- and beta-adrenoceptor 
agonists on NA release. Findings in non-neuronal tissue support this 
theory where beta-adrenoceptor agonists enhance adenylate cyclase 
activation leading to increased cAMP production (Perkins, 1973) and 
alpha2 _adrenoceptor agonists inhibit adenylate cyclase and decrease 
cAMP production (Jakobs, 1985). Thus, the ability of beta- 
adrenoceptor agonists to promote NA release and alpha2 ~adrenoceptor 
agonists to inhibit NA release may be a reflection of the effects 
these drugs have on neuronal cAMP production. In most tissues the 
proportion of nerve to effector cell is so small as to make it 
experimentally impracticable to attribute to the neuronal tissue a 
change in the cyclic nucleotide level which is also present to a large 
extent in non-neuronal tissue (Gillespie, 1980). The inability to
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measure cyclic nucleotide levels in neuronal tissue directly means 
that the role of cyclic nucleotides in modulating transmitter release 
has to be investigated indirectly by examining the effects of drugs, 
which alter cyclic nucleotide levels, on the release of transmitter.
The present study sought to determine whether cAMP was involved in 
modulating NA release from the sympathetic nerve terminals in the 
heart. The study also investigated the role of cGMP in modulating 
transmitter release in the atria. For these purposes, the effects of 
drugs that activate adenylate or guanylate cyclase, mimic cAMP or cGMP 
or inhibit the breakdown of these cyclic nucleotides were examined.
The ability of clonidine to inhibit NA release has previously been 
described. The study demonstrated the ability of isoprenaline the 
beta-adrenoceptor agonist to potentiate NA release. This facilitatory 
adrenoceptor, believed to be of the beta2 ~subtype is thought not to be 
activated by endogenous NA but rather by adrenaline in the circulation 
(Majewski, 1983). It has been proposed that the facilitation of NA 
release evoked by activation of presynaptic beta-adrenoceptors may be 
mediated through increased levels of neuronal cAMP (Langer, 1979).
O
The ability of IBMX to potentiate field stimulation-induced [ H]-NA 
overflow confirmed what previous studies have shown, namely that 
phosphodiesterase inhibitors enhance NA release during nerve 
stimulation (Cubeddu et al, 1975; Celuch et al, 1978; Johnston et al, 
1987). The cell permeant analogue of cAMP, 8-bromo-cAMP enhanced the 
field-stimulation induced release of [JH]-NA from the atria. However, 
since field stimulation results in release of both NA and ACh and 
since ACh exerts an inhibitory influence on NA release it was 
necessary to determine whether 8-bromo-cAMP was acting directly on the
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sympathetic nerve terminal to facilitate the release of NA, or whether 
it was acting on the cholinergic nerve terminal to inhibit ACh release 
so that less ACh was available to inhibit the release of NA. In such 
circumstances 8-bromo-cAMP would increase NA overflow. If, 
however, 8-bromo-cAMP could still produce an increase in [^H]-NA 
overflow when the cholinergic restraint on NA release was blocked by 
atropine then this would provide evidence for a facilitatory action 
of 8-bromo-cAMP on the adrenergic nerve terminal. The present study 
has shown that 8-bromo-cAMP does indeed potentiate field stimulation-
O
induced [ H]-NA overflow in the presence of atropine in the atria.
Thus, the study also examined the effect of forskolin on the field-
O
stimulated release of [ H]-NA. Forskolin activates adenylate cyclase 
leading to increased cAMP production (Seaman & Daly, 1981). Thus, if
cAMP is involved in promoting the release of NA then forskolin should
potentiate the release of [^H]-NA. Since it was necessary to dissolve 
forskolin in DMSO the effect of forskolin on [ H]-NA release was 
compared with that of DMSO alone. It was found that DMSO produced an
O
enhancement in the field-stimulated release of [ H]-NA and that 
forskolin produced no further increase in release. The study is 
unable to produce evidence implicating forskolin in promotion of 
transmitter release. The vehicle, DMSO, possibly masked any potential
O
effect of forskolin on [ H]-NA overflow and perhaps a different 
vehicle, for example ethanol, might not have produced such an 
undesirable effect.
Forskolin did have a powerful postsynaptic excitatory effect on the 
force of contraction of the atria, presumably because of its effect on 
adenylate cyclase in the effector tissue but the vehicle, DMSO, had no 
such effect. Other workers have reported that forskolin does enhance 
the stimulation-induced release of [^H]-NA (Hovevei-Sion et al, 1983).
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There seems little doubt, that increasing the concentration of 
intraneuronal cAMP by pharmacological means, results in an increase in 
noradrenaline release (Wooten et al, 1973; Cubeddu et al, 1975; 
Hentrich et al, 1985). In addition, activation of the presynaptic 
beta-adrenoceptor has also been linked to increased cAMP production 
which promotes the release of noradrenaline (Langer, 1981; Johnston 
et__al, 1987). However, the possibility that the presynaptic alpha2 _ 
adrenoceptor on the adrenergic nerve terminal, in the atria, is linked 
to adenylate cyclase is more controversial.
It has been shown previously that in non-neuronal tissues occupation 
of an alpha2 ~adrenoceptor causes dissociation of a trimeric guanine- 
nucleotide binding protein (Ni) and these subunits inhibit adenylate 
cyclase leading to a decrease in cAMP production (Dolphin, 1987).
,Since it appears that alpha2 ~adrenoceptors inhibit adenylate cyclase 
when they are situated post-synaptically, this study investigated if 
the same action on adenylate cyclase occurred following activation of 
presynaptic alpha2 -adrenoceptors. Previous studies have examined this 
hypothesis indirectly by using either cell permeable cAMP analogues to 
saturate the cell with cAMP (Johnston et al, 1987) or 
phosphodiesterase inhibitors to prevent the breakdown of cAMP (Cubeddu 
et al, 1975; Johnston et al, 1987). These studies found little 
evidence to suggest that cAMP is involved in alph^-adrenoceptor-
mediated presynaptic inhibition of transmitter release. A previous
study by Johnston and Majewski (1986) had however, found evidence
which suggested that presynaptic alpha-adrenoceptors were linked to 
adenylate cyclase.
A more direct approach is to use pertussis toxin purified from the 
bacteria Bordetella pertussis which abolishes alpt^-adrenoceptor
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agonist inhibition of adenylate cyclase in both membranes and intact 
cells (Katada et al, 1986). Pertussis toxin pretreatment leads to a 
loss of receptor-mediated inhibition of adenylate cyclase (Dolphin, 
1987). Thus, if the presynaptic alpha2 ~adrenoceptor is linked via a 
pertussis toxin sensitive guanine nucleotide binding protein to 
adenylate cyclase, then pretreatment with pertussis toxin should 
result in the abolition of the ability of clonidine to inhibit [3H]-NA 
overflow. The present study compared the ability of clonidine to 
inhibit field stimulation-induced [3H]-NA overflow from control atria 
and atria removed from rats pretreated with pertussis toxin.
The results showed that, in atria from pertussis toxin treated rats,
* * O
the ability of a low dose of clonidine to inhibit [ H]-NA overflow 
was abolished. At higher doses there was no difference in the ability 
of clonidine to inhibit overflow in control or pretreated atria. This 
anomalous result has three possible explanations. First, it is 
possible that the pertussis toxin pretreatment was ineffective and the 
apparent ability of pertussis toxin to abolish the effect of the low 
concentration of clonidine is an artefact. This possibility was 
examined by assessing the effectiveness of the pertussis toxin 
pretreatment on the cholinergically-mediated negative inotropic 
response to field stimulation of the atria. Pertussis toxin abolished 
this response to field stimulation and this is consistent with the 
ability of pertussis toxin to abolish the response to carbachol in rat 
atria (Endoh et al, 1985) and mouse atria (Musgrave et al, 1987). 
Secondly, since it appears that pertussis toxin pretreatment was 
effective, as indicated by the abolition of the cholinergic response, 
it is possible that the presynaptic alpha2 ~adrenoceptor is not linked 
to adenylate cyclase via a pertussis toxin sensitive inhibitory 
guanine nucleotide binding protein. Again, this would suggest that the
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"effect" at the lowest dose of clonidine was artefact. However, this 
interpretation would agree with a recent study which suggested that 
pertussis toxin did not attenuate alpha2 —adrenoceptor-mediated 
inhibition of noradrenaline release in mouse atria (Musgrave et al, 
1987). The third possibility is that the presynaptic alpha2 ~ 
adrenoceptor is linked to adenylate cyclase in such a way that 
pertussis toxin pretreatment abolishes the receptor-mediated 
inhibition and thus at low doses clonidine is unable to inhibit the 
release of NA. It is possible that at higher doses clonidine acts on 
presynaptic alpha^-adrenoceptors on the sympathetic nerve terminal 
which also inhibit the release of NA but which are unaffected by 
pertussis toxin pretreatment. Evidence exists for the presence of 
inhibitory alpha^-adrenoceptors on the cardiac sympathetic neurones in 
the rat (Docherty, 1984).
It is possible that a non-selective action at high doses of clonidine 
is masking the presynaptic effect of pertussis toxin pretreatment. 
Certainly, in non-peripheral tissue, such as hippocampal slices, 
pertussis toxin attenuated clonidine inhibition of stimulation-induced 
[3H]-NA release (Allgaier et al, 1985).
Given that the evidence for an involvement of cAMP in inhibition of 
transmitter release was slight, the study examined the possible role 
of cGMP and its modulation of transmitter release. The role in nerves 
of guanylate cyclase and cGMP is complex and currently undefined 
(Drummond, 1984). One report provided electrophysiological evidence 
for a calcium-dependent prejunctional role for cGMP possibly linked to 
an alpha-adrenergic receptor (O'Dea & Zatz, 1976). In this study it 
was found that in the rat pineal gland in vitro, both exogenous NA and 
high potassium caused an accumulation of cGMP in the whole gland. The
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effect was abolished by phenoxybenzamine or phentolamine and also by 
chronic sympathetic denervation. The authors suggested the effect may 
be associated with presynaptic alpha-adrenoceptor inhibition. A 
further transmitter release study in this preparation found that 
dibutyryl cGMP, a cell permeant derivative of cGMP, inhibited the 
potassium-evoked release of [3H]-NA. In addition, a specific cGMP 
phosphodiesterase inhibitor also inhibited the potassium-evoked 
release of [3H]-NA (Pelayo et al, 1978).
Contrary to the work cited above the present study found that sodium 
nitroprusside, which stimulates guanylate cyclase and cGMP formation 
(Rapaport & Murad, 1983) caused a dose-dependent potentiation of field
O
stimulation-induced release of [ H]-NA from the atria. In addition, 
it was also found that the cell permeant derivative of cGMP, 8-bromo-
O
cGMP also potentiated the field stimulation induced release of [ H]-NA 
overflow. These results apparently provide evidence implicating cGMP 
in the enhanced release of NA from sympathetic nerves in the atria.
If activation of guanylate cyclase promotes NA release, then the 
question arises as to where this enzyme is located. If this enzyme is 
in the sympathetic nerves it appears as if it might facilitate NA 
release. On the other hand, if the guanylate cyclase is located in 
the concomitantly-stimulated cholinergic nerves, then it could be 
involved in inhibiting ACh release, so that the restraining influence 
of ACh on NA release would be reduced and NA overflow would increase.
It is interesting to note that several recent studies (Loiacono et al, 
1985; Johnston & Majewski, 1986; Johnston et al, 1987; Musgrave et al, 
1987) that have examined the release of NA in the atria have failed to 
take into account the fact that field stimulation releases both NA
91
and ACh, These studies have formulated conclusions based on the 
principle that the drugs employed are acting solely on the adrenergic 
nerve terminals while ignoring the possible action of the drugs on the 
release of ACh.
The ability of drugs which mimic cGMP or prevent the breakdown of cGMP 
to enhance NA release has been reported previously (Cubeddu et al, 
1975). In this study 8-bromo-cGMP promoted the release of [^H]-NA 
from cat spleen. In addition 8-bromo-cGMP produced a concentration- 
dependent inhibition of phosphodiesterase activity in the whole 
preparation. It has been suggested therefore that 8-bromo-cGMP by 
inhibiting phosphodiesterase, prevented the breakdown of neural cAMP 
thus promoting transmitter release. However, since nerve terminal 
phosphodiesterase probably represents a very small fraction of the 
total phosphodiesterase present in the spleen, correlation between 
enhanced exocytosis and enzyme inhibition must be interpreted with 
caution (Cubeddu et al, 1975).
This is particularly true when it is possible that the drug reputedly 
inhibiting phosphodiesterase in the adrenergic nerve may have a 
completely different site of action. Thus, in the recent study by 
Johnston et al (1987) it was report that 8-bromo-cGMP and a selective 
cGMP phosphodiesterase inhibitor (M + B 22948) both increased the 
field stimulation-induced overflow of radioactivity from atria 
incubated in [3H]-NA. The explanation for such an effect was again 
that these drugs may act to inhibit cAMP dependent phosphodiesterase. 
This, undoubtedly, is a possibility, however, the report ignored the 
possibility that these drugs may act on the cholinergic nerve terminal 
to inhibit the release of ACh.
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Indirect evidence was obtained in the present study that suggested SNP 
was not acting directly on the adrenergic nerve and indeed was acting 
in some way through ACh to promote the field stimulated—induced 
release of [3H]-NA. Thus, SNP was able to reverse the inhibitory 
effects of the alpl^-adrenoceptor agonist clonidine but not the 
inhibitory effects of exogenous ACh on [3H]-NA release. If SNP 
inhibits ACh release, then such an effect would not interfere with the 
inhibitory effects of exogenous ACh on [3H]-NA overflow from the 
sympathetic nerves. In addition, the study examined the ability of 
SNP to potentiate field stimulation-induced [3H]-NA release in the 
presence of atropine, which, if used in a high enough concentration 
should remove the cholinergic-mediated restraint on NA release. SNP
O
was still able to a potentiate [ H]-NA release in the presence of a 
sub-maximal dose of atropine, however, at a high dose of atropine SNP 
was unable to further potentiate this response. This indicates that 
the net effects of SNP and atropine are similar, with atropine 
blocking the effects of ACh and SNP perhaps blocking the release of 
ACh. It also indicates that SNP and by extrapolation guanylate 
cyclase and cGMP have no direct influence on the release of NA from 
the sympathetic nerve terminals in the rat atria.
Direct evidence for an inhibitory effect of SNP on ACh release from 
cholinergic nerves was obtained by examining the effects of SNP on the 
field stimulation-induced release of [1Z*C] from atria previously in 
[l^cj-choline. The results show that SNP inhibited the release of 
[1Z*C] from field stimulated atria. However, in this experiment it is 
possible that the inhibitory effect was indirectly due to an increased 
release of endogenous NA resulting in an inhibition of ACh release due 
to increased activation of the presynaptic alpha-adrenoceptor on the 
cholinergic nerve terminal. Therefore, the ability of SNP to inhibit
[ C] overflow was examined again, this time in the absence of 
noradrenergic influence.
Thus, in the presence of the alpha-adrenoceptor antagonists, prazosin 
and yohimbine, which potentiated [^C] release, SNP retained its 
ability to inhibit the release of [14C]. This indicates that SNP, 
presumably by activating soluble guanylate cyclase and increasing 
intraneuronal cGMP levels inhibits the release of ACh from cholinergic 
nerve terminals. Normally, activation of guanylate cyclase may occur 
as a result of muscarinic cholinoceptor-mediated auto-inhibition by 
ACh, which elevates cGMP in nerves (Kebabian et al, 1975; Drummond, 
1984). It is not inconceivable that the presynaptic inhibitory 
muscarinic cholinoceptor situated in the cholinergic nerve terminal 
described in this study and by Wetzel et al (1985) is also linked to 
-guanylate cyclase such that activation of the receptor results in 
activation of the enzyme and increased cGMP levels leading to 
inhibition of ACh release.
Since the field stimulation-induced release of [1ZfC] was assumed to 
reflect that of ACh and since field stimulation in atria releases both 
ACh and NA simultaneously, a response to vagal stimulation, in the 
whole animal was sought and the ability of SNP to inhibit this
chronotropic response was investigated. Stimulation of the vagus 
nerve resulted in a decrease in heart rate in both pithed and
anaesthetised animals. Stimulation-induced bradycardia was greater in 
anaesthetised animals in which there was a higher basal heart rate due 
to the existence of a basal sympathetic tone. In pithed animals the 
cardio-accelerator nerves at C7-T1 in the spinal column could be
stimulated selectively by means of a spinal electrode. Such
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stimulation produced an increase in heart rate. As before, the effect 
of SNP on this, sympathetic, response was examined.
In anaesthetised animals stimulation of the vagus nerve produced a 
decrease in heart rate and this response was unaffected by intravenous 
(i.v.) administration of SNP. Administration of the alpha- 
adrenoceptor antagonists prazosin and yohimbine potentiated the 
vagally-induced bradycardia. This was presumably due to blockade of 
the alpha-adrenoceptors on the cholinergic nerve terminals that were 
tonically activated by the existing sympathetic tone. Under these 
circumstances SNP did inhibit the vagally-induced bradycardia. Thus, 
in anaesthetised rats SNP could inhibit the response to vagal 
stimulation in the presence of alpha-adrenoceptor antagonists. The 
effect was believed to be presynaptic since SNP did not affect the 
bradycardia which was induced by i.v. administration of ACh either in 
the absence or presence of prazosin and yohimbine.
The ability of SNP to inhibit the response to vagal stimulation in the 
presence of the alpha-adrenoceptor antagonists suggests that this 
effect of SNP is normally masked by the tonic sympathetic inhibitory 
influence on ACh release. It is perhaps possible that presynaptic 
alpha-adrenoceptor activation on the cholinergic nerve terminal and 
SNP affect the same intracellular pathway governing the release of 
ACh.
If it were true that SNP could inhibit vagal stimulation in absence of 
sympathetic influence on the release of ACh then in pithed rats, in 
vhich there exists no sympathetic tone, SNP should be able to inhibit 
the response to vagal stimulation in the absence of alpha-adrenoceptor 
antagonists. The study has shown that, in the pithed rat,
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administration of SNP inhibited the response to vagal stimulation at 
low frequencies of stimulation. In pithed rats, at higher frequencies 
of stimulation of the vagus nerve, a biphasic effect on heart rate 
occurred. This response consisted of a decrease in heart rate which 
was transient and soon developed into an increase in heart rate. The 
negative component of this response was blocked by atropine and the 
positive component was blocked by propranolol, suggesting that at this 
frequency of stimulation of the vagus excitation, of both cholinergic 
and adrenergic fibres occurred. When such a response occurred SNP 
only slightly inhibited the cholinergic component but markedly 
potentiated and prolonged the second sympathetic component. It 
appeared that this effect of SNP on the adrenergic component was 
indirect and, like the effect of SNP in isolated atria, was due to 
inhibition of ACh release. In the pithed rat i.v. administration of 
NA produced an increase in heart rate and this response was unaffected 
by SNP. This suggests that SNP did not potentiate the adrenergic 
component of the response to vagal stimulation by blocking NA uptake 
or by any post-synaptic effect.
Stimulation of the cardio-accelerator nerves in the pithed rat also 
resulted in tachycardia. This response was blocked by propranolol, 
inhibited by clonidine and potentiated by yohimbine. SNP, however, 
did not affect the response of the heart following stimulation from 
the spinal column of the cardio-accelerator nerves. Again, this 
result suggests that SNP was not acting directly on the sympathetic 
nerves to potentiate the sympathetic component following stimulation 
of the vagus. Rather, it seems that concomitant stimulation of 
cholinergic fibres is required before a potentiated sympathetic 
component can be observed.
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This response was therefore, similar to the effect of SNP on [3H]-NA
O
overflow whereby [ H]—NA release was potentiated due to inhibition of 
ACh release rather than a direct effect of SNP on sympathetic nerves. 
In the anaesthetised rat it appears that SNP can inhibit the response 
to vagal stimulation possibly by acting on the cholinergic nerves to 
inhibit the release of ACh. The effect does not seem to be post- 
synaptically mediated since the response to exogenous ACh was 
unaffected by SNP. However, the inhibitory effect of SNP following 
vagal stimulation in the anaesthetised rat appears to masked by the 
presynaptic inhibitory effect on ACh release exerted by an existing 
sympathetic tone. In the absence of such tone in the pithed rat the 
response to vagal stimulation, at a similar frequency, is inhibited by 
SNP. At a higher frequency of stimulation of the vagus in the pithed 
rat it appears that excitation of both cholinergic and adrenergic 
fibres occurs and under such conditions the sympathetic component is 
potentiated by SNP. The ability of SNP to potentiate the sympathetic 
component requires the simultaneous stimulation of cholinergic nerves.
This latter effect of SNP can be repeated by performing experiments on 
the field-stimulated, spontaneously beating paired rat atria. SNP 
potentiated the positive, adrenergically-mediated inotropic field 
stimulation-induced response. Administration of atropine, and 
consequently the removal of the cholinergic influence, resulted in the 
a loss of ability of SNP to potentiate the positive inotropic post­
stimulus response of the atria. SNP did not affect the basal rate or 
force of contraction of the spontaneously beating atria. Thus, once 
more, the ability of SNP to potentiate a sympathetically-mediated 
response requires a cholinergic influence. It appears that SNP itself 
acts to remove the cholinergic influence by inhibiting the release of 
ACh.
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The present study therefore, has provided evidence, which suggests 
that cAMP is involved in promoting the release of NA from adrenergic 
nerves. The results support the hypothesis that SNP inhibits release 
of ACh from cholinergic nerves and only indirectly potentiates NA 
release from sympathetic nerves due to ACh-mediated neuromodulation of 
NA release. This demonstrates the importance of considering the 
interactions that occur between the adrenergic and cholinergic nerves 
in the atria particularly when examining the effect of drugs that 
influence the release of the transmitters.
THYROXINE-INDUCED CHANGES IH SENSITIVITY
Thyroid hormones are known to influence the sensitivity of 
sympathetically-innervated tissues to agonists. Whereas most studies 
investigating the effects of these hormones have examined their 
effects on postsynaptic receptors, this study sought to determine 
whether or not chronic T^ pretreatment affected the sensitivity of 
presynaptic receptors. The study also re-examined the influence of
these hormones on post-synaptic receptor sensitivity.
T^ administration raised the levels of free T^ in the plasma and 
produced changes in the responsiveness of the rat atria to drugs 
acting both pre-and post—synaptically. This pretreatment raised the 
resting rate of beating of the isolated atria by approximately 50% and 
increased the sensitivity of the atria to the beta-adrenoceptor 
agonist isoprenaline. This supersensitivity was characterised by a
potentiation of the maximum response to isoprenaline with no shift in 
the position of the percentage/dose response curve. The parameter 
used to determine changes in sensitivity was the rate of beating which 
is potentiated by the pretreatment. This may explain why at
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relatively low doses isoprenaline produced little change in the rate 
of beating in atria removed from pretreated animals in comparison 
with controls.
The study also examined the effects of pretreatment on the
sensitivity of the spontaneously beating paired atria of the rat to 
the muscarinic cholinoceptor agonist carbachol. The results from this 
part of the study are complex. Pretreatment with T^ produced no 
displacement in the percentage/dose response curve for carbachol. 
When the results are expressed as the change in rate ( A b .P.M.) 
produced by the drug it appears that T^ pretreatment increased the 
maximum response to carbachol in atria from pretreated rats. This, 
however, is misleading since the inherent rate of beating in atria 
from T^ pretreated rats is higher than in control atria. It appears 
that the highest dose of carbachol (10”  ^ M) is sufficient to cause 
maximum inhibition of the rate of beating of the atria despite this 
inherent higher rate of beating in the atria from pretreated rats. 
Unlike the situation with isoprenaline where the increased inherent 
rate of beating appeared not to mask any changes in sensitivity 
particularly at high doses, in this case, with carbachol it is 
difficult to interpret the effect of T^ pretreatment on the 
sensitivity of the post-synaptic muscarinic receptor.
One possible means of overcoming this problem would be to examine the 
inotropic effects of agonists on paced left atria. This method was 
employed to determine the effect of T^ pretreatment on the sensitivity 
of the post-synaptic alpha1-adrenoceptor in the atria. Chronic pre­
treatment with T^ resulted in a decreased sensitivity of the atria to 
the alpha^-adrenoceptor agonist phenylephrine. The inotropic response 
of the paced atria to phenylephrine could be inhibited by the alpha-^-
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adrenoceptor antagonist prazosin. The results of this study confirm 
that hyperthyroidism increases the sensitivity of the heart to beta— 
adrenoceptor agonists and decreases the sensitivity to alpha— 
adrenoceptor agonists as has been shown previously ( Kunos, 1977; 
Gibson, 1981; McNeill, 1987). The observation that T^ pretreatment 
potentiated the inherent rate of beating of the atria suggest the 
actions of the thyroid hormones are complex and may exert 
intracellular effects in addition to those at the level of the 
receptor (Tse et al, 1980; McNeill, 1987).
The study also compared responses to field stimulation in control 
atria and atria from pretreated rats. T^ pretreatment potentiated the 
positive noradrenergic component of the inotropic post-stimulus 
response to field stimulation in atria from pretreated rats. In 
addition, the negative cholinergic component of the inotropic post­
stimulus response was inhibited by T^-pretreatment. These effects may 
be due to supersensitivity of the post-synaptic beta-adrenoceptors 
and/or subsensitivity of the post-synaptic muscarinic cholinoceptors. 
It is also possible, however, that enhanced effectiveness of the 
positive inotropic response is due to a subsensitivity of presynaptic 
alpha-adrenoceptors on the adrenergic nerve terminal which would 
result in a decreased ability to inhibit NA release. The study has 
shown that T^ pretreatment reduced the ability of clonidine to inhibit 
the positive inotropic post stimulus response in the presence of 
atropine and also reduced the ability of clonidine to inhibit the 
overflow of [3H] in atria previously incubated in [ H]-NA. T^ 
pretreatment did not, however, affect the ability of ACh to inhibit 
the field—stimulated—induced overflow of [ H] from atria incubated in
[3h ]-n a .
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The possibility remains that pretreatment exerted a toxic effect on 
nerve terminals by removing the inhibitory capacity of presynaptic 
receptors, this is an unlikely explanation of the results, since the 
ability of clonidine to inhibit responses was affected while that of 
ACh was not. A non-specific effect on nerve-endings would have been 
more likely to affect the inhibitory capacity of both drugs similarly.
pretreatment did not appear to significantly affect the ability of 
either clonidine or ACh to inhibit the field-stimulated induced 
release of [^C] from atria previously incubated in [ -choline. 
Although further investigation is merited it is possible that the 
effects of are confined not only to the sympathetic nerves but 
perhaps also only the inhibitory adrenoceptors. Speculation aside, 
the results of the study confirm those of previous work in the mouse 
vas deferens where pretreatment also resulted in a subsensitivity 
,to clonidine (Forsyth et al, 1986).
The results also cast some doubt on the hypothesis of Kunos (1977) 
which suggests that there exists a single adrenoceptor that can 
interconvert to the alpha or beta state according to the circulating 
levels of T^. The results of this study suggest that hyperthyroidism 
not only affects postsynaptic receptors but perhaps also presynaptic 
receptors. Thus, the tachycardia seen in hyperthyroidism may be due 
not only to post-synaptic supersensitivity of beta^adrenoceptors but 
also to subsensitivity of presynaptic alpha2 ~adrenoceptors, the latter 
resulting in a diminished restraint on NA release. However, the 
possibility remains that interconversion between alpha- and beta- 
adrenoceptors may occur not only post—synaptically but also 
presynaptically on the nerve terminal.
In conclusion, the results of the study have confirmed that complex 
presynaptic interactions exist between the sympathetic and cholinergic 
nerves in the heart. The speculative hypothesis of Rand et al (1975, 
1980) whereby ACh and NA exert autoinhibition and mutual cross 
inhibition of transmitter release is confirmed. The study has also 
implicated cAMP and cGMP in modulation of the release of NA and ACh. 
In addition, it has demonstrated the necessity to consider the complex 
interactions between the two sets of nerves when examining the role of 
cyclic nucleotides in transmitter release. Finally, the effect of 
chronic T^ pretreatment on the response of the heart to pre-and post- 
synaptic agonists were examined. The study provided evidence that 
hyperthyroidism produced sensitivity changes not only post- 
synaptically but also pre-synaptically.
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